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Streptococcus suis infects pigs worldwide and may be zoonotically transmitted to 
humans with a mortality rate of up to 20%. Methicillin-resistant Staphylococcus aureus 
(MRSA) and Streptococcus pyogenes (group A streptococci – GrAS) cause potentially 
fatal human diseases. These are just three of the many Gram-positive pathogens for 
which resistance to leading antibiotics has emerged. The goal of this work was to develop 
a novel antimicrobial treatment to combat these and other antibiotic-resistant pathogens. 
We identified a novel bacteriophage lysin, derived from an S. suis phage termed 
PlySs2 (phage lysin from S. suis 2). This thesis is divided into four main sections 
detailing PlySs2: characterization (chapter 2); activity against S. suis (chapter 3); broad 
lytic activity (chapter 4); and efficacy in vivo (chapter 5). 
PlySs2 has an N-terminal CHAP catalytic domain and a C-terminal SH3b binding 
domain. It is stable at 50°C for 30 min, 37°C for >24 h, 4°C for 15 days, and -80°C for 
>7 months; it maintained full activity after 10 freeze-thaw cycles. 
PlySs2 displays potent lytic activity against most strains of S. suis including the 
type strain S735, the pathogenic serotype 2, strain 10, and the pathogenic serotype 9 
strain 7997. At 64 μg/ml, PlySs2 reduced multiple strains of S. suis by 6-logs within 1 
hour in vitro. PlySs2 exhibited a minimum inhibitory concentration (MIC) of 32 μg/ml 
for S. suis strain S735 and 64 μg/ml for strain 7997. While resistance to gentamicin was 
observed after systematically increasing levels of gentamicin in an S. suis culture, the 
same protocol resulted in no observable resistance to PlySs2. 
The bacteriophage lysin PySs2 also exhibits broad lytic activity against MRSA, 
vancomycin-intermediate S. aureus (VISA), Streptococcus suis, Listeria, Staphylococcus 
simulans, Staphylococcus epidermidis, Streptococcus equi, Streptococcus agalactiae 
(group B streptococci – GBS), S. pyogenes, Streptococcus sanguinis, group G 
streptococci (GGS), group E streptococci (GES), and Streptococcus pneumoniae. PlySs2 
at 128 μg/ml in vitro reduced MRSA and S. pyogenes by 5-logs and 3-logs within 1 hour 
respectively, and exhibited a minimum inhibitory concentration (MIC) of 16 μg/ml for 
MRSA. Serially increasing exposure of MRSA and S. pyogenes to PlySs2 or mupirocin 
resulted in no observed resistance to PlySs2 and resistance to mupirocin.  
The relevance of our in vitro work was confirmed with multiple in vivo 
experiments. Using a single 0.1-mg dose of PlySs2, the colonizing S. suis strain 7997 was 
reduced from the murine intranasal mucosa by >4 logs; a 0.1-mg dose of gentamicin 
reduced S. suis by <3-logs. A combination of 0.05 mg PlySs2 + 0.05 mg gentamicin 
reduced S. suis by >5-logs. In protecting against mixed infections, a single, 2-mg dose of 
PlySs2 protected 92% (22/24) of the mice in a bacteremia model of dual MRSA and S. 
pyogenes infection.  
This is the first known lysin with broad activity against multiple serotypes and 
strains of S. suis, making it a vital tool in the treatment and prevention of S. suis 
infections in pigs and humans. To date, no other lysin has shown such notable broad lytic 
activity, stability, and efficacy against multiple, leading, human bacterial pathogens; 











To my wife, Chanel 
To my children 





I am especially grateful to my advisor and mentor, Dr. Vincent Fischetti. He fully 
empowered me to freely execute all of the work in this thesis. As a mentor, he guided 
with patience, while always demanding the highest standard of scientific investigation. In 
addition, he valued my nonscientific endeavors, which afforded me an exceptionally 
fulfilling graduate experience. 
I am grateful to my faculty advisory committee, comprised of Dr. Erec Stebbins 
and Dr. Howard Hang, for their wise insights and consistent guidance. Also, I am 
thankful for Dr. David Donovan graciously accepting a position on my committee as the 
external examiner. 
I am incredibly thankful for Dr. Jonathan Schmitz. From my first day in the 
laboratory, he helped me launch my thesis project – even while writing his own thesis 
during my first months. Through the years, Dr. Chad Euler provided invaluable 
contributions to the in vivo work. I am also grateful for Nathan Franck for his excellent 
technical expertise. Dennis Spencer was both a sounding board and friend in times of 
uncertainty. I was amazed by each of the excellent summer students I mentored here at 
Rockefeller. Magid Mohamed, Khoi Nguyen, Karen Tong, and Haaris Khan each 
performed at the level of a PhD candidate. I am indebted to all the members of the 
Fischetti Laboratory who collectively established a collaborative, constructive 
environment where I was comfortable proposing any study. 
I was fortunate to work with Dr. Jaap Wagenaar and Dr. Niels Dekker of Utrecth 
University, as well as Dr. Sünje Pamp and Dr. David Relman of Stanford University in 
collaborations. It has been an honor to work with Dr. Raymond Schuch of ContraFect 
v 
 
Corporation, and I am eager to see how this scientific story continues to develop. I 
highlight specific, scientific contributions at the end of each chapter. 
I am thankful to the Rockefeller community for providing: scientific expertise; a 
comfortable living environment; and safety for my family. This was largely due to my 
exceptional fellow coworkers in housing, security, the mailroom, and the Child and 
Family Center. In the Dean’s Office, Dr. Sidney Strickland, Dr. Emily Harms, Marta 
Delgado, Kristen Cullen, Cris Rosario, Courtney McBride, and Stephanie Fernandez have 
been incredibly supportive from my application to the program through my thesis 
defense, enabling me to focus solely on science. To my friends throughout New York 
City, I am thankful for how you have helped me view my work in ways I had never 
considered. 
This thesis is the culmination of education spanning three decades. I would never 
have sought a PhD, if it had not been for Mr. Terry Nusbaum teaching me biology in high 
school years ago. At Howard University, Dr. Winston Anderson inspired me to make 
discoveries that had never been made; potentially benefitting thousands. Dr. Cathy 
Drennan of Massachusetts Institute of Technology revealed the full process of science to 
me – from writing grants to reviewing others’ publications.  
I am grateful to the Howard Hughes Medical Institute (HHMI) Gilliam fellowship 
for funding all five years of my graduate study. The supplemental training and 
networking at HHMI conferences immeasurably augmented the generous financial 
support. This work was also made possible by multiple grants from the US National 
Institutes of Health. 
vi 
 
Most of all, I would like to thank my wife, Chanel Gilmer, who has journeyed 
with me through every day of this doctoral work. From applying to graduate school to 
writing my thesis, she has been an unwavering source of passionate encouragement and 
insightful perspective. My children have been wonderful joys throughout my study 
bringing meaning to my every day. And finally, I am forever indebted to my parents who 







TABLE OF CONTENTS 
DEDICATION……..…………………………………………………………………....iii 
ACKNOWLEDGEMENTS ............................................................................................ iv 
TABLE OF CONTENTS ............................................................................................... vii 
LIST OF FIGURES ....................................................................................................... xiv 
LIST OF TABLES ......................................................................................................... xvi 
LIST OF ABBREVIATIONS ...................................................................................... xvii 
1 CHAPTER 1 – INTRODUCTION ............................................................................ 1 
1.1 Gram-positive pathogens ....................................................................................... 1 
1.1.1 Streptococcus suis ........................................................................................... 1 
1.1.1.1 Pathogenesis ............................................................................................. 1 
1.1.1.2 Zoonosis ................................................................................................... 2 
1.1.2 Streptococcus pyogenes - GrAS ...................................................................... 4 
1.1.2.1 Colonization ............................................................................................. 4 
1.1.2.2 Pathogenesis ............................................................................................. 4 
1.1.2.3 Mortality .................................................................................................. 5 
1.1.3 Staphylococcus aureus .................................................................................... 5 
1.1.3.1 Pathogenesis ............................................................................................. 5 
1.1.3.2 Transmission ............................................................................................ 6 
1.1.4 Other Gram-positive pathogens ...................................................................... 6 
1.1.4.1 Streptococcus agalactiae – GBS ............................................................. 7 
1.1.4.2 Listeria monocytogenes ........................................................................... 7 
1.2 Antibiotics .............................................................................................................. 8 
viii 
 
1.2.1 Treatment ........................................................................................................ 8 
1.2.2 Resistance ....................................................................................................... 9 
1.3 Phage Lytic Enzymes ........................................................................................... 13 
1.3.1 Phage ............................................................................................................. 13 
1.3.1.1 Life cycles .............................................................................................. 13 
1.3.1.1.1 Lysogenic cycle .............................................................................. 14 
1.3.1.1.2 Lytic cycle ....................................................................................... 14 
1.3.1.2 Role in nature ......................................................................................... 15 
1.3.1.3 Shaping molecular biology .................................................................... 15 
1.3.1.4 Therapeutic application .......................................................................... 16 
1.3.2 Lysins ............................................................................................................ 17 
1.3.2.1 Discovery ............................................................................................... 18 
1.3.2.2 Structure ................................................................................................. 20 
1.3.2.3 Activity .................................................................................................. 20 
1.3.2.4 Current Lysins ........................................................................................ 24 
1.3.2.4.1 LySMP – S. suis phage enzyme ...................................................... 25 
1.3.2.4.2 ClyS – staphylococcal phage enzyme ............................................. 27 
1.3.2.4.3 PlyC – streptococcal phage lysin .................................................... 27 
1.4 Peptidoglycan ....................................................................................................... 28 
1.5 AIMS.................................................................................................................... 33 
2 CHAPTER 2 – LYSIN CHARACTERIZATION .................................................. 34 
2.1 MATERIALS AND METHODS ......................................................................... 34 
2.1.1 Discovery ...................................................................................................... 34 
ix 
 
2.1.1.1 Genomic sequence analysis ................................................................... 34 
2.1.1.2 Cloning ................................................................................................... 34 
2.1.1.3 Candidate assay ...................................................................................... 34 
2.1.2 Expression ..................................................................................................... 35 
2.1.3 Purification .................................................................................................... 35 
2.1.4 Characterization ............................................................................................ 36 
2.1.4.1 Optimization .......................................................................................... 36 
2.1.4.2 Stability .................................................................................................. 36 
2.2 RESULTS ............................................................................................................ 37 
2.2.1 Identification ................................................................................................. 37 
2.2.2 Purification .................................................................................................... 40 
2.2.3 Characterization ............................................................................................ 42 
2.2.3.1 Optimization .......................................................................................... 42 
2.2.3.2 Stability .................................................................................................. 48 
2.3 ACKNOWLEDGEMENTS ................................................................................. 53 
3 CHAPTER 3 – STREPTOCOCCUS SUIS SUSCEPTIBILITY ............................ 54 
3.1 MATERIALS AND METHODS ......................................................................... 54 
3.1.1 Bacterial strains ............................................................................................. 54 
3.1.2 Lytic activity against S. suis.......................................................................... 57 
3.1.3 Bactericidal assay.......................................................................................... 57 
3.1.4 MIC assay ..................................................................................................... 58 
3.1.5 Resistance ..................................................................................................... 58 
3.2 RESULTS ............................................................................................................ 59 
x 
 
3.2.1 Lytic activity against S. suis.......................................................................... 59 
3.2.2 Bactericidal assay.......................................................................................... 65 
3.2.3 MIC assay ..................................................................................................... 67 
3.2.4 Resistance ..................................................................................................... 69 
3.3 ACKNOWLEDGEMENTS ................................................................................. 71 
4 CHAPTER 4 – BROAD GRAM-POSITIVE SUSCEPTIBILITY ....................... 72 
4.1 MATERIALS AND METHODS ......................................................................... 72 
4.1.1 Bacterial strains ............................................................................................. 72 
4.1.2 Lytic activity ................................................................................................. 78 
4.1.3 Bactericidal assay.......................................................................................... 78 
4.1.4 MIC assay ..................................................................................................... 78 
4.1.5 Resistance ..................................................................................................... 79 
4.1.6 PlySs2 catalytic domain lytic assay .............................................................. 79 
4.1.7 Fluorescent binding assay ............................................................................. 80 
4.2 RESULTS ............................................................................................................ 81 
4.2.1 Lytic activity ................................................................................................. 81 
4.2.2 Bactericidal assay.......................................................................................... 87 
4.2.3 MIC Assay .................................................................................................... 90 
4.2.4 Resistance ..................................................................................................... 92 
4.2.5 PlySs2 catalytic domain lytic assay .............................................................. 94 
4.2.6 Fluorescent binding assay ............................................................................. 96 
4.3 ACKNOWLEDGEMENTS ................................................................................. 99 
5 CHAPTER 5 – IN VIVO MODELS ...................................................................... 100 
xi 
 
5.1 MATERIALS AND METHODS ....................................................................... 100 
5.1.1 Intranasal mucosa model............................................................................. 100 
5.1.1.1 S. suis colonization............................................................................... 100 
5.1.1.2 Treatment ............................................................................................. 100 
5.1.2 Mixed bacteremia model............................................................................. 101 
5.1.2.1 MRSA + GrAS Infection ..................................................................... 101 
5.1.2.2 Treatment ............................................................................................. 101 
5.2 RESULTS .......................................................................................................... 102 
5.2.1 Intranasal mucosa decolonization ............................................................... 102 
5.2.2 Mixed bacteremia protection ...................................................................... 105 
5.3 ACKNOWLEDGEMENTS ............................................................................... 109 
6 CHAPTER 6 – DISCUSSION................................................................................ 111 
6.1 Lysin Characterization ....................................................................................... 111 
6.1.1 Identification ............................................................................................... 111 
6.1.2 Purification and Stability ............................................................................ 111 
6.1.3 Catalytic Domain ........................................................................................ 112 
6.1.4 Binding Domain .......................................................................................... 112 
6.2 S. suis susceptibility to PlySs2 ........................................................................... 113 
6.2.1 Lytic activity ............................................................................................... 113 
6.2.2 Implications of lytic activity ....................................................................... 114 
6.3 Broad Gram-positive susceptibility ................................................................... 115 
6.3.1 Lysin specificity .......................................................................................... 115 
6.3.2 Broad PlySs2 lytic activity.......................................................................... 116 
xii 
 
6.3.2.1 S. aureus susceptibility to PlySs2 ........................................................ 117 
6.3.2.2 Streptococcal susceptibility to PlySs2 ................................................. 117 
6.3.3 Broad bactericidal activity against streptococci and staphylococci ............ 118 
6.4 Absence of in vitro resistance to PlySs2 ............................................................ 118 
6.4.1 No observable in vitro resistance to PlySs2 in S. suis ................................ 118 
6.4.2 No observable in vitro resistance to PlySs2 in MRSA or S. pyogenes ....... 119 
6.5 Intranasal mucosa decolonization ...................................................................... 119 
6.5.1 Lysin alone or with antibiotic ..................................................................... 120 
6.5.2 Prophylaxis ................................................................................................. 121 
6.6 Mixed bacteremia protection ............................................................................. 121 
6.6.1 Implications................................................................................................. 122 
6.6.2 PlySs2 applications ..................................................................................... 124 
6.7 Other tests .......................................................................................................... 125 
6.8 Importance ......................................................................................................... 125 
7 CHAPTER 7 – CONCLUSIONS ........................................................................... 127 
8 APPENDIX .............................................................................................................. 129 
8.1 PlySs2 minipig protection from S. suis .............................................................. 129 
8.1.1 BACKGROUND ........................................................................................ 129 
8.1.2 MATERIALS AND METHODS ................................................................ 129 
8.1.2.1 PlySs1 + PlySs2 preliminary drug interaction ..................................... 129 
8.1.2.2 Minipig treatment................................................................................. 129 
8.1.3 RESULTS ................................................................................................... 130 
8.1.3.1 PlySs1 + PlySs2 preliminary drug interaction ..................................... 130 
xiii 
 
8.1.3.2 Minipig treatment................................................................................. 132 
8.1.4 DISCUSSION ............................................................................................. 134 
8.1.5 ACKNOWLEDGEMENTS ........................................................................ 134 
8.2 Rat oral cavity metagenomics ............................................................................ 134 
8.2.1 BACKGROUND ........................................................................................ 135 
8.2.2 MATERIALS AND METHODS ................................................................ 135 
8.2.3 RESULTS ................................................................................................... 137 
8.2.4 DISCUSSION ............................................................................................. 141 
8.2.5 ACKNOWLEDGEMENTS ........................................................................ 143 
8.3 Structural studies ................................................................................................ 143 
8.3.1 BACKGROUND ........................................................................................ 143 
8.3.2 METHODS ................................................................................................. 143 
8.3.3 RESULTS ................................................................................................... 144 
8.3.4 ACKNOWLEDGEMENTS ........................................................................ 146 
8.4 DNA AND AMINO ACID SEQUENCES ........................................................ 147 




LIST OF FIGURES 
 
Figure 1.1 Reports of individual human S. suis infections have recently increased. .......... 3 
Figure 1.2 Periodic emergence of S. aureus antibiotic resistance. ................................... 10 
Figure 1.3 New systemic antibacterial agents approved by the US FDA. ........................ 12 
Figure 1.4 Lytic cycle versus lysin treatment. .................................................................. 22 
Figure 1.5 Gram-positive cell wall cross-section diagram. .............................................. 29 
Figure 1.6 Peptidoglycan molecular composition. ........................................................... 31 
Figure 2.1 PlySs2 amino acid sequence and structure. ..................................................... 38 
Figure 2.2 PlySs2 enzymatic domain alignment............................................................... 39 
Figure 2.3 PlySs2 corresponded to bands at ~26 kDa on SDS-PAGE. ............................ 41 
Figure 2.4 PlySs2 was found to have the most acute activity in basic pH levels. ............ 43 
Figure 2.5 NaCl does not augment PlySs2 activity. ......................................................... 45 
Figure 2.6 Dithiothreitol (DTT) does not inhibit PlySs2 activity. .................................... 46 
Figure 2.7 Minimal ion depletion from EDTA inhibits PlySs2 activity. .......................... 47 
Figure 2.8 PlySs2 is stable under a variety of conditions. ................................................ 49 
Figure 2.9 PlySs2 is stable and active after ten, consecutive freeze-thaws. ..................... 52 
Figure 3.1 PlySs2 lysed almost all strains of S. suis over 30 minutes. ............................. 60 
Figure 3.2 PlySs2 lysed almost all strains of S. suis over 60 minutes. ............................. 61 
Figure 3.3 S. suis strain S735 exposed to various concentrations of PlySs2. ................... 63 
Figure 3.4 S. suis strain 7997 exposed to various concentrations of PlySs2. ................... 64 
Figure 3.5 PlySs2 was bactericidal to nearly all strains of S. suis. ................................... 66 
Figure 3.6 S. suis 7997 and S735 did not develop resistance to PlySs2 in vitro. ............. 70 
xv 
 
Figure 4.1 PlySs2 displayed activity against various species. .......................................... 83 
Figure 4.2 PlySs2 displayed activity against various species over 60 minutes. ............... 85 
Figure 4.3 PlySs2 was bactericidal across multiple species of bacteria. .......................... 89 
Figure 4.4 MRSA, MSSA, and GrAS did not acquire resistance to PlySs2 in vitro. ....... 93 
Figure 4.5 Lytic effect of PlySs2 Full Length VS Catalytic Domain ............................... 95 
Figure 4.6 PlySs2-BD Flurescence and comparison to PlySs2-CD activity. ................... 97 
Figure 5.1 PlySs2 and gentamicin may act additively to reduce S. suis in vivo. ............ 103 
Figure 5.2 PlySs2 protected mice from mixed MRSA and GrAS infection. .................. 106 
Figure 8.1 PlySs1 + PlySs2 drug interaction. ................................................................. 131 
Figure 8.2 Pig deaths over two weeks. ........................................................................... 133 
Figure 8.3 There were two predominant phyla in the oral cavity. .................................. 139 





LIST OF TABLES 
 
Table 1.1 Timeline of lysin discovery .............................................................................. 19 
Table 3.1 Strains used in the S. suis susceptibility study .................................................. 55 
Table 3.2 The MIC of PlySs2 for S. suis serotypes and strainsa ....................................... 68 
Table 4.1 Strains used in this study .................................................................................. 73 








B. anthracis Bacillus anthracis 
B. cereus Bacillus cereus 
B. subtilis Bacillus subtilis 
B. thuringiensis Bacillus thuringiensis 
BCA bicinchoninic acid (assay) 
BD binding domain 
BHI brain heart infusion (media) 
Buffer A 15 mM PB, pH 8.0  
Buffer B 15 mM PB, pH 6.7  
Buffer C 50 mM PB, pH 7.4 
Buffer D 
Buffer E 
20 mM PB, pH 7.4 
20 mM glycine-NaOH, pH 9.3 
CA-MRSA community-acquired methicillin-resistant S. aureus 
CD catalytic domain 
CFU colony forming unit 
CHAP cysteine-histidine amidohydrolase/peptidase (domain) 








E. coli Escherichia coli 
E. faecalis Enterococcus faecalis 
E. faecium Enterococcus faecium 
EDTA ethylenediaminetetraacetic acid 
FDA Food and Drug Administration (United States) 
FL full-length (enzyme) 
GBS Streptococcus agalactiae 
GCS group C streptococci 
GES group E streptococci 
GGS group G streptococci 
GrAS group A streptococci, S. pyogenes 
kD kilodaltons 
L. acidophilus Lactobacillus acidophilus 
L. gasseri Lactobacillus gasseri 
L. monocytogenes Listeria monocytogenes 
L. rhamnosus Lactobacillus rhamnosus 





Log fold kill -log[(number of cells surviving under test 
condition)/(number of cells surviving under control 
condition)] 
MH Mueller-Hinton (media) 
MIC minimum inhibitory concentration 
MRS de Man, Rogosa, and Sharpe (media) 
MRSA methicillin-resistant S. aureus 
MSSA methicillin-sensitive S. aureus 
OD optical density 
OD ratio Treated OD600 / Untreated OD600 
P. aeruginosa Pseudomonas aeruginosa 
PBS phosphate buffered saline 
PlyC a multimeric lysin of the C1 bacteriophage 
PlySs2 Phage lysin from Streptococcus suis 2 
Rcf relative centrifugal force 
Rpm revolutions per minute 
S. agalactiae Streptococcus agalactiae 
S. aureus Staphylococcus aureus 
S. dysgalactiae Streptococcus dysgalactiae 





S. epidermidis Staphylococcus epidermidis 
S. equi Streptococcus equi 
S. equi zooepidemicus Streptococcus equi zooepidemicus 
S. gordonii Streptococcus gordonii 
S. mutans Streptococcus mutans 
S. oralis Streptococcus oralis 
S. pneumoniae Streptococcus pneumoniae 
S. pyogenes Streptococcus pyogenes 
S. rattus Streptococcus rattus 
S. sanguinis Streptococcus sanguinis 
S. simulans Staphylococcus simulans 
S. sobrinus Streptococcus sobrinus 
S. suis Streptococcus suis 
ST serotype 
VISA vancomycin-intermediate S. aureus 






1 CHAPTER 1 – INTRODUCTION 
1.1 Gram-positive pathogens 
Gram-positive pathogens such as Streptococcus pyogenes (group A streptococci – 
GrAS), Staphylococcus aureus, Streptococcus suis, Streptococcus agalactiae (group B 
streptococci – GBS), and Listeria monocytogenes are responsible for millions of serious 
and sometimes fatal infections worldwide. Additionally, resistance to conventional 
antibiotics has been on the rise, resulting in increased rates of infection, morbidity, 
mortality, and treatment costs. Consequently, new therapeutic methods need to be 
developed to reduce the antibiotic pressure on these pathogens. Our laboratory studies 
many different genus and species of these bacteria in hopes of finding novel therapeutics  
1.1.1 Streptococcus suis 
1.1.1.1 Pathogenesis 
The zoonotic Gram-positive pathogen S. suis causes sepsis and meningitis in pigs 
and humans. S. suis was first isolated from septicemic pigs and subsequently found to be 
biochemically distinct from other streptococci (de Moor 1963). After recent 
reclassification (Hill et al. 2005), there are 33 serotypes distinguished by variations in the 
capsular polysaccharide synthesis (cps) locus (Liu et al. 2013). Serotype 2, strain 10 and 
serotype 9, strain 7997 of S. suis have been most often associated with disease, with 
strain 7997 causing an increasing proportion of the infections worldwide (Silva et al. 
2006, Wu, Zhang, and Lu 2008, Gottschalk et al. 2010). Pigs intranasally colonized with 
S. suis may transmit the pathogen to humans and piglets causing pneumonia, septicemia, 
or meningitis within days (Dekker et al. 2013, Arends and Zanen 1988, Gottschalk et al. 




of pigs develop meningitis or septicemia. 
1.1.1.2 Zoonosis 
In particular, the serotype 9 strain 7997 has been associated with increasing 
reports of zoonotic transmission from pigs to humans (Sriskandan and Slater 2006). The 
earliest human case was reported in 1968; since then, over 700 human cases have been 
reported in multiple continents with a 5-20% mortality rate (Figure 1.1) (Perch, 
Kristjansen, and Skadhauge 1968, Sriskandan and Slater 2006, Yu et al. 2006, Trottier et 
al. 1991). In a 2-month 2005 outbreak in China, among 203 human cases reported, the 
median time from exposure to infection was 2.2 days, but ranged from 3 hours to 14 days 







†The 215 cases officially reported during the 2005 outbreak in Sichuan Province and the 
25 cases of 1998 outbreak in Jiangsu Province, both in China, were excluded from the 
analysis to accurately follow the evolution of S. suis human disease. 
‡Only 11 months of 2009 were included. 
 
Figure 1.1 Reports of individual human S. suis infections have 
recently increased. 
Annual, confirmed, reported human cases of S. suis infection have increased over the past 
decade. This may be due, in part, to increased reporting rather than an actual increase in 
S. suis infection. Adapted from Future Microbiology (Gottschalk et al. 2010) with 




Humans and pigs can be topically and systemically treated with penicillin or 
gentamicin with success, but S. suis isolates resistant to these antibiotics have emerged 
(Cantin et al. 1992, Varela et al. 2013, Gottschalk et al. 2010). Further, there is no 
vaccine for S. suis (Fittipaldi et al. 2012). As such, S. suis appears to be developing a 
more consistent presence in human populations and these infections may become more 
difficult to treat. 
1.1.2 Streptococcus pyogenes - GrAS 
1.1.2.1 Colonization 
Streptococcus pyogenes is a group A beta hemolytic streptococci. Over 30% of the 
human population may be colonized with Streptococcus pyogenes in the upper 
respiratory tract – the only known site of benign colonization (Mandell et al. 2005). 
Colonized individuals are much less likely than severely sick persons to transmit illness 
(Mandell et al. 2005). 
1.1.2.2 Pathogenesis  
S. pyogenes annually infects over 750 million people (Carapetis et al. 2005), 
resulting in 25% mortality  among the ~650,000 cases that progress to severe infection 
(Carapetis et al. 2005, Cunningham 2000, Bessen et al. 2011). This pathogen is 
responsible for a broad range of infections such as pharyngitis, impetigo, scarlet fever, 
erysipelas, cellulitis, toxic-shock syndrome, and necrotizing fasciitis; and it can lead to 
serious sequelae such as rheumatic fever, and acute glomerulonephritis (Swedo et al. 





The mortality rates can be very high for these infections, including 20% for 
necrotizing fasciitis, and 50% for toxic-shock syndrome (Bisno, Brito, and Collins 2003). 
Rheumatic fever, acute glomerulonephritis, and forms of obsessive-compulsive disorder 
are non-suppurative sequelae associated with an S. pyogenes infection (Swedo et al. 
1997). Invasive streptococcal infections  and rheumatic fever outbreaks have seen a rise 
worldwide since the 1980’s (Kavey and Kaplan 1989). 
1.1.3 Staphylococcus aureus 
1.1.3.1 Pathogenesis 
Of all the Gram-positive pathogens, Staphylococcus aureus has become the most 
difficult to treat. S. aureus is a Gram-positive facultative anaerobe that causes most 
Staphylococcus infections in man. Human anterior nares (nostrils) are typically the 
primary sites of S. aureus colonization, along with other moist openings on the body 
serving as additional sites for entry (White and Smith 1963, Kluytmans, van Belkum, and 
Verbrugh 1997, von Eiff et al. 2001, Wertheim et al. 2005a). 
S. aureus is capable of producing severe, secondary infections in 
immunocompromised individuals, as well as causing disease in otherwise healthy people. 
Besides skin and soft tissue infections (SSTIs), S. aureus can cause sepsis, pneumonia, 
necrotizing fasciitis, pyomyositis, endocarditis, toxic shock syndrome, and scalded skin 
syndrome (White and Smith 1963, Wertheim et al. 2005b). These infections are usually 
treated with methicillin, mupirocin, or vancomycin. Unfortunately, many S. aureus 
strains, such as methicillin-resistant S. aureus (MRSA) and (less often) vancomycin-




standard treatment (Howden et al. 2010), making them even more difficult to treat with 
available antimicrobials (Howden et al. 2010). 
1.1.3.2 Transmission 
Further exacerbating the problem, MRSA is readily transmitted between patients in 
hospitals (Coates, Bax, and Coates 2009). MRSA account for more than 50% of hospital 
isolates causing pneumonia and septicemia (Klein, Smith, and Laxminarayan 2007), 
particularly in intensive care units, resulting in 30-40% mortality (Tiemersma et al. 
2004, Laupland, Ross, and Gregson 2008). It is the primary cause of lower respiratory 
tract infections, surgical site infections, and ~19,000 deaths/year in the US alone 
(Fischetti 2008, Klein, Smith, and Laxminarayan 2007). 
While health-care-associated MRSA strains usually infect susceptible patients, 
community-associated MRSA (CA-MRSA) can infect healthy individuals (CDC 
1999, Herold et al. 1998, Zetola et al. 2005, David and Daum 2010). CA-MRSA strains 
are often more virulent and are capable of causing more severe diseases in humans and 
animal models (Adem et al. 2005, Miller et al. 2005, Li et al. 2009, Voyich et al. 2005). 
Distinct strains of CA-MRSA are epidemic in Europe, North America, Oceania, and 
other regions (Herold et al. 1998, Vandenesch et al. 2003, Tristan et al. 2007). The MW2 
strain (pulsed-field type USA400) is the prototypical CA-MRSA, having contributed to 
the incipient outbreak of CA-MRSA in the USA, which led to an epidemic (CDC 
1999, Deleo et al. 2010). There is currently no vaccine for S. aureus (Middleton 2008). 
1.1.4 Other Gram-positive pathogens 
Zoonotic Gram-positive pathogens include: Streptococcus equi (strangles – an 




and meningitis in pigs and humans). The pathogenic S. suis serotype 9 strain 7997 has 
been associated with increasing reports of zoonotic transmission from pigs to humans 
(Sriskandan and Slater 2006). Humans and pigs have been treated with penicillin or 
gentamicin, but S. suis isolates resistant to these antibiotics exist (Cantin et al. 1992). S. 
suis may develop a consistent presence in human populations in years to come. 
There are many other Gram-positive human pathogens, including: Streptococcus 
sanguinis (dental plaque and caries); S. sanguinis (endocarditis); Group G Streptococcus; 
group E Streptococcus; and S. pneumoniae (pneumonia, otitis media, meningitis, 
bacteremia, sepsis, endocarditis, peritonitis, and cellulitis). 
1.1.4.1 Streptococcus agalactiae – GBS 
Another beta-hemolytic Gram-positive streptococcus, Streptococcus agalactiae 
(Group B streptococci – GBS) contains an antiphagocytic capsule as its primary virulence 
factor (Yeung and Mattingly 1984, Rubens et al. 1987). S. agalactiae can exist in the 
human gastrointestinal system, occasionally colonizing secondary sites like the vagina in 
over 33% of women (Boyer et al. 1983, Meyn, Krohn, and Hillier 2009). The colonizing 
S. agalactiae can infect a neonate during birth resulting in bacterial septicemia, making 
early-onset S. agalactiae the primary cause of death in newborns for over 4 decades 
(Lancefield and Hare 1935, Fry 1938, Hare and Colebrook 1934),(Zangwill, Schuchat, 
and Wenger 1992). The current standard of practice exposes the mother to antibiotics that 
further the likelihood of resistance. 
1.1.4.2 Listeria monocytogenes 
A recent Gram-positive pathogen outbreak involving Listeria monocytogenes 




food-borne illness outbreak in the US since the 1970’s (Baertlein 2011). Most individuals 
contract listeriosis after consumption of contaminated food, facing a mortality rate of 20-
30%, even with antibiotic therapy (Schuppler and Loessner 2010, Hof, Szabo, and Becker 
2007). Listeria survives well in food processing systems and the human gastrointestinal 
tract, readily adjusting to swift changes in pH, salinity, and temperature (Schuppler and 
Loessner 2010, Ramaswamy et al. 2007, Dieterich et al. 2006).  
1.2 Antibiotics 
1.2.1 Treatment 
Many bacteria interact with molds, plants, or other bacteria. As a defense, these 
hosts have developed antibiotics – relatively small molecules that impede bacterial 
proliferation. Antibiotics may be bacteriostatic or bactericidal. A minimum inhibitory 
concentration (MIC) assay determines the bacteriostatic concentration of an antibiotic. A 
colony forming unit assay evaluates log fold killing to determine bactericidal efficacy 
(MBC). 
Derivatives of molds and plants have been used to treat bacterial infections for 
millennia. The antiseptic properties of these antibiotic molecules began to be formally 
described and empirically evaluated throughout the late 19th century. Scientists began to 
focus on a small molecule excreted by mold that seemed to inhibit or kill bacteria. In 
1923, Sir Alexander Fleming worked with a chemist to successfully purify penicillin. By 
1945, in his Nobel Lecture, Fleming was already warning of antibiotic resistance. 
Antibiotics can be used to treat a wide range of bacterial pathogens in humans. 




associated illnesses is Clostridium difficile-associated enteritis (Kuijper et al. 2006). 
Further, antibiotics can be rendered ineffective when bacteria develop resistance. 
1.2.2 Resistance 
Today, there are hundreds of antibiotics available to treat numerous pathogens. 
Nonetheless, over-prescription of these drugs where they are not needed or beneficial is 
an issue. For example, viruses account for the vast majority of pharyngitis (sore throat) 
infections. Nonetheless, doctors prescribe antibiotics for sore throat nearly 60% of the 
time (Barnett and Linder 2014). While wiser use of antibiotics may decrease rates of 
resistance, antibiotic resistance existed before widespread use of antibiotics (Lederberg 
and Lederberg 1952). Unfortunately, the US Centers for Disease Control and Prevention 
did not begin tracking antibiotic resistance in a national report until 2013 (CDC 2013). 
Therefore, it is still difficult to evaluate just how severe antibiotic resistance has become 
and for how long. 
Through mutation and horizontal gene transfer, bacteria are consistently acquiring 
resistance to leading antibiotics. In the case of S. aureus, there has been a consistent 
acquisition of resistance over time (Figure 1.2). Antibiotics act by inhibiting the synthesis 
of the bacterial cell wall, proteins, or nucleic acids. They may also alter the plasma 
membrane or metabolite activity to assert a lethal effect. Bacteria may be impervious to 







Figure 1.2 Periodic emergence of S. aureus antibiotic resistance. 
For S. aureus, clinical resistance tends to emerge 5-10 years after the introduction of a 
novel antibiotic. There has been a steady decrease in the number of effective antibiotics 
to treat both community- and hospital-associated strains. S. aureus clone “phage type 
80/81” was the most prevalent of the penicillin-resistant strains (which expressed a 
plasmid-encoded penicillinase and caused the first wave of resistance). Adapted from 





Innate resistance refers to the inherent characteristics of a species of bacteria that 
enable it to resist the action of an antibiotic. For instance Pseudomonas aeruginosa and 
Acinetobacter baumannii have uniquely impervious outer membranes that decrease the 
influx of many antibiotics (Fernandez and Hancock 2012). 
Acquired resistance occurs when bacteria incorporate new genetic sequences by 
acquiring new DNA (via plasmids, integrons, etc.) or mutations. If bacteria acquire 
genetic material encoding an antibiotic inhibitor, they will express that inhibitor, and thus 
be resistant. 
Adaptive resistance occurs when bacteria change the expression of genes and/or 
proteins to withstand the presence of an antibiotic. For instance, up-regulating the 
expression of efflux pumps may keep intracellular concentrations of the antibiotic below 
bacteriostatic levels. 
Antibiotic resistant bacteria could cause pandemics similar to those seen before 
the advent of antibiotic therapeutics. Compounding the problem, fewer systemic 
antibiotics are being approved by the US FDA (Figure 1.3). There are three main 
approaches to address the development of resistant bacteria: preventing antibiotic-
resistant infections; tracking resistant bacteria with improved diagnostics and 
surveillance; and developing new antimicrobials. One new antimicrobial approach 
involves the oldest infectious agents discovered, bacteriophages, along with their 











Figure 1.3 New systemic antibacterial agents approved by the US 
FDA. 
There has been a steady decrease in the number of approved systemic antimicrobials over 
the past 5 years. This is partially due to a decreasing reservoir of antimicrobials, but 
economics and regulation have also affected recent output. Image taken from (Boucher et 





1.3 Phage Lytic Enzymes 
1.3.1 Phage 
Bacteriophages (phages) are viruses that infect bacteria. They are also the most 
numerous genetic elements on Earth, numbering 1031. Every 48 hours, half of the bacteria 
on Earth are destroyed by phages (Rohwer, Prangishvili, and Lindell 2009, Hendrix 
2002). Having evolved over eons to infect and lyse bacteria, phages have been proposed 
as therapeutics ever since they were observed by Frederick Twort in 1915 and fully 
discovered by Félix d'Hérelle in 1917. Bacteria have evolved numerous defenses against 
viruses, exhibiting resistance to phages so rapidly that a cocktail of phages is required for 
treatment. Further, the cocktail must be changed during a treatment regimen. 
Nevertheless, the therapeutic effect of phages is found in their ability to lyse bacteria. 
This involves molecules to which bacteria are not able to easily evolve resistance. 
1.3.1.1 Life cycles 
As viruses, all phages are structured with nucleic acid packaged in protein. In 
order to replicate and assemble progeny, they must infect a host. Replication and the 
release of viral progeny can take place without killing the bacterial host (e.g. filamentous 
bacteriophages called inoviruses) (Waldor, Friedman, and Adhya 2005). Nonetheless, 
nearly all discovered viruses exhibit two life cycles - lysogenic and lytic. Phages have the 
potential to enter a particular life cycle upon initial infection based on the number of viral 





1.3.1.1.1 Lysogenic cycle 
 In the lysogenic (i.e. temperate or benign) phase, the proviral nucleic acid remains 
in the host as a dormant episome or as a sequence integrated into the host’s genomic 
DNA. Two important processes are required for lysogeny: integration into a specific 
location in the bacterial genome (Van Duyne 2005), and repression of lytic-pathway 
protein transcription (Waldor, Friedman, and Adhya 2005). 
 Prophage may replicate along with the host for many cycles (with copies of the 
prophage being passed on to host progeny) during the lysogenic phase. Reactivation of 
the phage occurs when it excises from the genome and lytic pathway proteins commence 
translation. Phages reactivate when their host is compromised due to DNA damage, 
environmental stress, or other host factors (Broudy, Pancholi, and Fischetti 2002). 
However, phages may spontaneously reactivate without stressors at a rate of ~10-4 to 10-5 
cells (Waldor, Friedman, and Adhya 2005). 
 If they remain integrated for a long period, prophage can be damaged or 
attenuated. If prophage lose the ability to reactivate, they may interminably persist as a 
part of the bacterium’s prophage genome (Casjens 2003). Strains of bacteria will carry 
and express attenuated prophage genes if those genes prove advantageous. Although this 
is deleterious to the original phage, it represents another way that phages play a vital role 
in the evolution of bacteria. 
1.3.1.1.2 Lytic cycle 
 The lytic (i.e. virulent) phase includes phage replication, viral assembly, and 
progeny release. In order to replicate, the phage takes over its host’s transcriptional 




the replicated phage nucleic acids. In most characterized pathways, after assembly, the 
phage induces lysis of the bacterial host, releasing phage progeny. Macroscopically, this 
appears as a clearing zone, or plaque, when phages are overlaid with susceptible bacteria 
on agar. 
1.3.1.2 Role in nature 
As discussed above phages play numerous, vital roles in the global microbiome. 
As the largest reservoir of genomic information, phages are responsible for most of the 
genetic exchange between living organisms. As previously alluded, phages encode many 
genes including virulence factors that can be advantageous to the host during viral 
lysogeny (Breitbart et al. 2004). Examples of such virulence factors are the S. pyogenes 
superantigens causing toxic shock, which are derived from prophage (Novick, Christie, 
and Penades 2010). 
1.3.1.3 Shaping molecular biology 
The ability of phages to transmit DNA has enabled experiments involving phages 
to guide the field of molecular biology from its inception as a discipline. The process of 
genetic mutation was elucidated by observing the development of phage-resistant E. coli 
(Luria and Delbruck 1943, Lederberg and Lederberg 1952). Further, in 1952, Hershey 
and Chase used T2 phage to confirm Avery’s finding that DNA is the heritable genetic 
macromolecule for all life (Avery, Macleod, and McCarty 1944). Phage subcomponents 
currently play a daily role in molecular biology as ligases, kinases, and polymerases. Due 
to their narrow host-specificity, phages are currently used to identify and type many 




1.3.1.4 Therapeutic application 
Phages have been used to treat infections in humans since their discovery in 1917. 
Due to a variety of factors, biologists and clinicians had trouble optimizing phage therapy 
for widespread use. There were successful trials against pathogens in Eastern Europe, but 
the results did not gain traction in the West (Sulakvelidze, Alavidze, and Morris 2001). 
With the arrival of antibiotics in the 1940’s, US research in therapeutic phages subsided.  
The pervasive emergence of antibiotic-resistant bacteria forced a reevaluation of 
phage therapy application toward the end of the 20th century. Early work in the US 
included animal models of E. coli and Pseudomonas aeruginosa infections (Smith and 
Huggins 1982, 1983, Soothill 1994). Phages have now been tested through double-
blinded phase II clinical trials against P. aeruginosa causing chronic otitis (Wright et al. 
2009) with safety in all patients and efficacy in those treated. A single, 2.4 ng dose of 6 
bacteriophages were able to improve the condition of 92% of the patients over 6 weeks, 
and led to the infection subsiding altogether in 25% of the patients (Wright et al. 2009). 
Phase I safety trials have also begun in the US (Rhoads et al. 2009, Bruttin and Brussow 
2005, Merabishvili et al. 2009). 
It has also been shown that the same benefits of phage therapy in humans translate 
to veterinary applications as well (Johnson et al. 2008). Finally, phage may also treat 
plant pathogens, which the phage already target and lyse in nature (Balogh et al. 2010). 
The US EPA has already approved phage cocktails to control Xanthomonas and 
Pseudomonas infections in tomatoes and pepper. A cocktail of phages has been approved 
by the US FDA to be included in packaged meat and cheese to prevent/control 




Interestingly, phages are the only antimicrobial agent that amplifies itself during 
therapeutic delivery.  
Phage specificity is also a limitation, as physicians rarely know the pathogen 
causing an infection before recommending treatment. Also, bacteria readily develop 
resistance to a single phage lineage, necessitating a cocktail for rapid bacterial treatment. 
The US FDA prefers to approve homogenous treatments rather than heterogeneous 
cocktails. 
Bacteria have co-evolved with phages, building up multiple defenses against 
them. Alternatively, exogenous bacteriophage lysins mediate lysis in a pathway that 
differs from phages (as discussed below), so bacteria should not readily develop 
resistance. This has been confirmed in (Loeffler, Nelson, and Fischetti 2001, Schuch, 
Nelson, and Fischetti 2002, Pastagia et al. 2011). 
1.3.2 Lysins 
Alternative therapies must be developed to mitigate the sharp increase in 
antibiotic resistance among Gram-positive bacteria including S. suis and S. aureus. Novel 
antimicrobial sources include enzyme-based antibiotics (“enzybiotics”) such as phage 
lytic enzymes (endolysins, or simply “lysins”) (reviewed in (Fischetti 2010) and 
(O'Flaherty, Ross, and Coffey 2009). These peptidoglycan hydrolases (catalyzing a 
variety of specific bonds) are encoded by virtually all double-stranded DNA phages.  
Bacteriophages encode lysins to hydrolyze the peptidoglycan bonds in the 
bacterial cell wall after phage progeny replicate inside the infected host bacterium 
(Wang, Smith, and Young 2000). Disruption of the cell wall leads to osmotic lysis of the 




When applied exogenously, purified lysins are able to access and degrade the 
bonds in the cell wall of Gram-positive bacteria, because they lack the outer membrane 
found in Gram-negative bacteria (Fischetti 2008). Besides chemical agents, lysins kill 
bacteria more rapidly than any known biological compound (Nelson, Loomis, and 
Fischetti 2001, Loeffler, Nelson, and Fischetti 2001, Fischetti 2005). Lysins typically 
demonstrate high specificity, with lethal activity directed against the species that the 
lysin-encoding phage infects (Fischetti 2008, Nelson, Loomis, and Fischetti 2001, Daniel 
et al. 2010, Loeffler, Nelson, and Fischetti 2001, Cheng et al. 2005). Therefore, lysins 
should not perturb the host’s normal flora as would broader-acting antibiotics (Fischetti 
2008). 
1.3.2.1 Discovery 
It was nearly a century after their initial identification and extraction before lysins 
were tested in vivo. This delay is due primarily to the emergence of antibiotics and 
technological challenges. The identification, purification, and production of enough 










Table 1.1 Timeline of lysin discovery 
Discovery Reference 
  
Phage lytic agent first extracted Felix d‘Hérelle 1921 
Phage virolysin differs from host lytic enzyme (Ralston et al. 1955) 
Isolated antigenically-distinct lytic enzymes (Ralston and McIvor 1964) 
First lysin amino acid sequence (Tsugita and Inouye 1968) 
Lysin purified by ion exchange chromatography (Doughty and Mann 1967) 
First lysin nucleotide sequence cloned (Owen et al. 1983) 







Gram-positive lysins usually have two domains, a catalytic N-terminal domain, 
and a C-terminal binding domain. This structural orientation is discussed in more detail in 
section 2.2.1 below. Some lysins have multiple units made of one subcomponent, such as 
PlyC. Others, usually staphylococcal lysins, will have multiple catalytic domains linked 
to one binding domain (Navarre et al. 1999). In most characterized lysins, the binding 
domain confers specificity, making the first interaction with cell wall components. This 
enables the catalytic domain to hydrolyze bonds in the cell wall. The full structure for 
Cpl-1 free and bound to choline indicate that the binding domain attaching to choline 
induces a conformational change orienting the catalytic domain for efficient 
peptidoglycan hydrolysis (Hermoso et al. 2003). 
1.3.2.3 Activity 
Today, lysins can be cloned from viral prophage sequences within bacterial 
genomes, recombinantly expressed in Escherichia coli, purified, and used for treatment 
(Beres and Musser 2007, Nelson, Loomis, and Fischetti 2001, Fischetti 2010). With 
advances in sequencing, one can screen the published bacterial sequences and identify 
candidate lysin sequences found in lysogens through homology analysis with known 
lysin sequences with standard algorithms (e.g. Blast, Pfam). Furthermore, complete 
phage genomes are being published more frequently than ever totaling 600+ in the NCBI 
database as of early 2014. As described by (Schmitz 2011), bioinformatic analyses can 
utilize metadata from public databases for lysin gene localization, identification, 




When applied exogenously, these enzymes are able to access the peptidoglycan 
layer in the Gram-positive cell envelope (due to the lack of an outer membrane) and 
produce the same lytic effect as when they are expressed inside the bacterial cell for 












Figure 1.4 Lytic cycle versus lysin treatment. 
(A) Left: Phage-mediated host lysis enables the virions (in red) to escape after 
replication. Right: Recombinant lysins are able to exogenously lyse Gram-positive 
bacteria just as lysins expressed within their host. (B) Electron micrograph (EM) of cells 
after phage-mediated lysis. (C) EM of cells after lysin-mediated lysis. Image modified 



















Unlike antibiotics, an important feature of phage lysins is their rapid, lethal effect 
on bacteria (Nelson, Loomis, and Fischetti 2001, Loeffler, Nelson, and Fischetti 
2001, Fischetti 2005). Lysins are notable for the potency and specificity they demonstrate 
– generally, toward the species that the encoding phage infects or closely related 
organisms (Daniel et al. 2010, Nelson, Loomis, and Fischetti 2001, Loeffler, Nelson, and 
Fischetti 2001, Cheng et al. 2005, Fischetti 2008). As such, they presumably exert a less-
dramatic affect on the normal nonpathogenic flora in the host than broad spectrum 
antibiotics (Fischetti 2008). Lysins kill bacteria quicker than any known non-chemical 
agents. While no lysin has yet been FDA-approved, these enzymes could be used to treat 
antibiotic-resistant bacteria. To date, no lysin has shown broad in vivo activity against 
multiple species of bacterial pathogens. 
1.3.2.4 Current Lysins 
Numerous lysins have been tested in vitro. They’ve shown activity against 
Bacillus anthracis, Bacillus cereus, Listeria monocytogenes, Staphyloccous aureus, 
Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes, 
Streptoccus suis, and Streptococcus uberis among other species (Garcia et al. 
1987, Navarre et al. 1999, Gaeng et al. 2000, Loeffler, Nelson, and Fischetti 
2001, Nelson, Loomis, and Fischetti 2001, Schuch, Nelson, and Fischetti 2002, Pritchard 
et al. 2004, Cheng et al. 2005, O'Flaherty et al. 2005, Korndorfer et al. 2006, Pritchard et 
al. 2007, Porter et al. 2007, Celia, Nelson, and Kerr 2008, Daniel et al. 2010, Schmelcher, 
Tchang, and Loessner 2011, Donovan et al. 2006, Donovan, Lardeo, and Foster-Frey 
2006, Mao et al. 2013, Rodriguez et al. 2011). Most are N-acetylmuramoyl-L-alanine 




Of these, many have been tested in vivo including PlyC, PlyGBS, PlyPH, Cpl-1, 
PAL, MV-L, CHAPK, LysGH15, ClyS, P-27/HP, and a few chimeras (Nelson, Loomis, 
and Fischetti 2001, Cheng et al. 2005, Schuch, Nelson, and Fischetti 2002, Yoong et al. 
2006, Loeffler, Nelson, and Fischetti 2001, Loeffler and Fischetti 2003, Rashel et al. 
2007, Fenton et al. 2011, Daniel et al. 2010, Gu et al. 2011, Gupta and Prasad 
2011, Schmelcher et al. 2012). Most lysins have been tested in murine decolonization 
models. Further, Cpl-1 (a pneumococcal lysin) has been shown to be synergistic with 
another pneumococcal lysin Pal in vivo (Loeffler and Fischetti 2003, Jado et al. 2003). 
Likewise, ClyS, a staphylococcal lysin displays synergy with the antibiotic oxacillin 
(Daniel et al. 2010). 
It has been shown that lysins delivered to animals systemically remain active for 
approximately 20 minutes (Loeffler, Djurkovic, and Fischetti 2003). Delivering a foreign 
protein to the bloodstream of animals will elicit an immunogenic effect. Nonetheless, 
rabbit hyperimmune serum raised against Cpl-1 does not inhibit Cpl-1 lytic activity 
(Loeffler, Djurkovic, and Fischetti 2003). The activity of Cpl-1 does not decrease as it 
remains active within the highly immune serum. This was also seen in experiments using 
a staphylococcal-specific lysin (Rashel et al. 2007). Loessner (Loessner et al. 2002) 
found that the binding domain of a listeria-specific phage enzyme has the nanomolar 
substrate affinity of an IgG molecule. This may partially explain why the action of the 
enzyme is not inhibited even in highly immune serum. 
1.3.2.4.1 LySMP – S. suis phage enzyme 
Two phages (Ss1 and SMP) infecting S. suis have been previously isolated. The 




serotype 2 strain 89-999 (Harel et al. 2003). An Ss1 lysin has not been identified, but the 
lysin of another S. suis phage has been developed. Ma and Lu isolated a lytic phage 
(SMP) after sequencing the 36 kb genome of S. suis retrieved from nasal swabs of 
healthy pigs (Ma and Lu 2008). SMP displayed narrow specificity, targeting just 2/24 S. 
suis serotype 2 strains. From SMP, Ma and Lu cloned and recombinantly expressed the 
SMP lysin (LySMP), which contains five cysteine residues thought to form 
intramolecular disulfide bridges. LySMP displayed in vitro bacteriolytic activity against 
many S. suis serotypes. Unfortunately, the recombinant LySMP only folds properly  after 
the addition of reducing agents, which may limit its potential for in vivo trials (Wang, 
Sun, and Lu 2009). Since then, it has been tested against biofilms in vitro, but not in vivo 
(Meng et al. 2011). 
Of the currently reported S. suis lysins, none have been shown to have activity 
against more than 3 serotypes of S. suis, nor have they been shown to decolonize animals 
in vivo (Harel et al. 2003, Ma and Lu 2008, Wang, Sun, and Lu 2009, Meng et al. 2011). 
Recently, our lab discovered a phage lytic enzyme from an S. suis prophage with broad 
activity against various pathogenic Gram-positives, which was named PlySs2 (Phage 
lysin from S. suis 2) (Gilmer et al. 2013). In this thesis, we characterize the activity of 
PlySs2 against S. suis and test this lysin’s ability to decolonize S. suis from murine nasal 
passages. Further, we show that this enzyme protected mice from a mixed bacteremic 
infection of methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus 
pyogenes, neither of which were found to develop resistance to PlySs2 in vitro (Gilmer et 




1.3.2.4.2 ClyS – staphylococcal phage enzyme 
Several lysins have also been developed against MRSA (Daniel et al. 
2010, O'Flaherty et al. 2005, Rashel et al. 2007). A staphylococcal-specific chimeric 
lysin, ClyS was previously developed in our lab from the bacteriophages Twort and Φ
NM3 lysins (Daniel et al. 2010). ClyS displays activity against S. aureus, MSSA, MRSA, 
S. epidermidis, S. simulans, and S. sciuri. It is very specific to staphylococci, as it 
displays no activity against species of streptococci or bacilli. In vivo, it has been used to 
remove MRSA from C57BL/6J mice nasally colonized with ~5 × 109 CFU by ~2 logs. It 
has also been shown to protect mice from septicemia-induced death alone and 
synergistically with oxacillin.  
1.3.2.4.3 PlyC – streptococcal phage lysin 
A lytic agent from C1 phage (Krause 1957), PlyC is one of the most effective 
lysins discovered. PlyC displays lytic activity against groups A, C, and E streptococci, 
but registers essentially no lytic activity against other bacteria. Just 10 ng is able to 
sterilize ~107 live S. pyogenes (Nelson, Loomis, and Fischetti 2001). Further, it has been 
shown to protect mice inoculated with 107 CFU S. pyogenes from colonization (Nelson, 
Loomis, and Fischetti 2001). This lysin also differs from all other published lysins in its 
114 kD size – much larger than the 25-40 kD size of most phage lysins. Eight PlyCB (~8 
kD) subunits form a nonamer with a single, distinct PlyCA (~50 kD) gene product to 
form the active PlyC molecule (Nelson et al. 2006). 
To date, however, no lysin has shown high lytic activity against multiple species 
of different bacterial pathogens. While developing a lysin with activity against the 




against a wide range of Gram-positive pathogens, and in vivo efficacy against S. suis, 
MRSA and S. pyogenes. 
1.4 Peptidoglycan 
Bacterial cell walls provide shape, size, and defense. All of the nutrients that 
come into a bacterial cell traverse the plasma membrane, so an amenable surface area to 
volume ratio is essential. If the cell is too large, there is not enough surface area for the 
exchange of nutrients to maintain metabolic equilibrium inside the cell. If the cell is too 
small, there is too much surface area without enough volume for intracellular processes. 
The role of the cell wall in maintaining cell shape also affects surface area to volume 
ratio. A circular shape favors volume, and an elongated shape favors surface area. 
Bacteria are often hypotonic to their surroundings. This creates up to 10-25 atm of 
pressure, which would easily destroy the fluid plasma membrane if the cell were not 
encased by a wall. Finally, the cell wall acts as a physical barrier protecting the cell from 
physical and chemical stress. 
Bacteria are divided into two, large, taxonomic categories according to their cell 
wall layers. Gram-negative bacteria have a plasma membrane, peptidoglycan layer, cell 
envelope and possibly a capsule. Gram-positive bacteria lack an outer envelope, so their 







Figure 1.5 Gram-positive cell wall cross-section diagram. 
From the extracellular space to the cytoplasm, the Gram-positive cell wall includes layers 
of peptidoglycan (blue) covering the plasma membrane composed of phospholipids 
(heads in pink, tails in black spirals). This organization contrasts with the Gram-negative 
cell wall, which has a thinner layer of peptidoglycan and a cell envelop that shields the 
peptidoglycan from the extracellular space. Image modified and used with permission 




The strongest (most rigid) structural feature of the bacterial cell wall is made of 
peptidoglycan. This macromolecule is composed of a polymeric carbohydrate backbone 
of repeating N-Acetylglucosamine (GlcNAc) N-Acetylmuramic acid (MurNAc) 
disaccharides (Vollmer, Blanot, and de Pedro 2008). Penta-/tetra-peptide stems connect 
to MurNAc on the backbone (Figure 1.6A). These stems can form cross-links or cross-
bridges adding structural stability to the peptidoglycan cell wall (Figure 1.6B). The 
backbone is highly conserved among most bacteria, but the cross-bridge can widely vary 












Figure 1.6 Peptidoglycan molecular composition. 
(A) The E. coli peptidoglycan structure repeats through the cell wall. The yellow 
highlight inscribes the monomer, a disaccharide tetrapeptide. The red lettering highlights 
a cross-linked peptide. (B) Comparison between E. coli (left) and S. aureus (right) 
peptidoglycan dimers linked by their stems. From top to bottom, there is a disaccharide 
backbone, tetrapeptide stem, cross-link (for E. coli) or cross-bridge (pentaglycine for S. 
aureus), tetrapeptide stem, and disaccharide backbone. Images modified from (Vollmer, 
















 Lysins can catalyze any of the bonds in Figure 1.6. Endo-β-N-
acetylglucosaminidases and N-acetylmuramidases catalyze bonds between the 
carbohydrate subunits. Endopeptidases hydrolyze stem or cross-bridge peptides, and N-
acetylmuramoyl-L-alanine amidases cut the bond joining the disaccharide to the peptide 
stem ((Loessner 2005, Young 1992, Fischetti 2010)). 
1.5 AIMS 
For most of the 20th century, antibiotics effectively treated bacterial infections. 
With the emergence of widespread antibiotic resistance, bacteriophages provide an 
alternative antimicrobial. Rather than using the entire phage, lysins provide a simpler, 
more effective treatment. 
Our first objective was to find a novel lysin with activity against S. suis. In 
characterizing this lysin in vitro, we discovered its efficacy against a variety of disparate 
species including S. aureus, S. pyogenes, and other Gram-positive pathogens. We 
biochemically characterized the lysin over ranges of temperature, salt, and pH. We also 
tested this lysin to ensure that resistance would not readily emerge. 
Given its utility, we proceeded to develop novel in vivo models to expand lysin 
applications for decolonization, with antibiotics, treatment of bacteremia, against two 
infections, and with two lysins against two infections. To lysin technology, we hope to 





2 CHAPTER 2 – LYSIN CHARACTERIZATION 
2.1 MATERIALS AND METHODS 
2.1.1 Discovery 
2.1.1.1 Genomic sequence analysis 
There are over 11 completed S. suis genomes in the NCBI database. Dr. Jonathan 
Schmitz analyzed the published sequences of S. suis strains to locate potential phage 
lysins within prophage regions. The theoretical translation of each open reading frame 
(ORF) was evaluated with BlastP and Pfam, revealing a single candidate of interest. 
Through sequence analysis and functional screening, we confirmed a new phage lysin 
from S. suis (termed PlySs2). 
2.1.1.2 Cloning 
The candidate lysin gene (PlySs2 from S. suis strain 89/1591) was PCR-cloned 
from genomic DNA with the following primers: AATGCTAGCCTGATACACAGTTAG 
AGACC (forward) and CCTAAGCTTCTTTTCACAAATCATAATCCCCAG (reverse). 
The underlined nucleotides represent engineered restriction sites (NheI and HindIII), 
which were cut with the corresponding enzymes (NEB, Ipswich, MA) to clone PlySs2 
into the pBAD24 expression plasmid (pBAD24_PlySs2) encoding ampicillin-selection 
and arabinose-induction. The pBAD24_PlySs2 vector was transformed into E. coli 
TOP10 cells (Invitrogen). 
2.1.1.3 Candidate assay 
The aforementioned E. coli clone was grown as a patch on LB-agar supplemented 
with 0.2% arabinose, permeabilized by a 10-minute exposure to chloroform vapor, and 




zone around the E. coli patch confirmed active recombinant expression of PlySs2 (Wang, 
Sun, and Lu 2009). 
2.1.2 Expression 
For PlySs2 expression and purification, the above clone was propagated in LB 
broth (37°C, 220 rpm aeration) with 100 μg/ml ampicillin. Recombinant expression was 
induced at OD600 ~0.8 by addition of arabinose (0.2%, final concentration). Following 
overnight incubation, the cells were pelleted at 10,722 rcf for 20 mins and resuspended in 
15 mM phosphate buffer (PB), pH 8.0 (buffer A) supplemented with protease inhibitor 
cocktail tablets (Roche). Cells were lysed with an EmulsiFlex C-5 homogenizer. The 
homogenate was centrifuged at 1,723 rcf for 20 mins. After debris removal via 
ultracentrifugation (35,000× G, 1 hr), the supernatant was adjusted to pH 7.4 with the 
addition of  ~4 volumes of buffer A. 
2.1.3 Purification 
The sample was passed through a HiTrap Fast Flow diethylaminoethyl (DEAE) 
anion-exchange column (General Electric) equilibrated with 15 mM PB, pH 7.4. The 
flow-through (which contained the desired PlySs2) was subjected to ammonium sulphate 
precipitation at 225 g/l (40% saturation). The precipitated protein was resolubilized in 40 
ml of 15 mM PB, pH 6.7 (buffer B) for every liter of initial E. coli culture to prevent 
precipitation. This solution was dialyzed extensively against buffer B with 12-14 kD 
dialysis tubing (Spectrum Laboratories) to remove any remaining ammonium sulphate. 
Finally, the dialysate was passed through a HiTrap Fast Flow carboxymethyl (CM) 
cation-exchange column (General Electric). The CM column was washed in buffer B + 




The presence of PlySs2 was confirmed by lytic activity (clearing zones on agar 
plates containing embedded, autoclaved S. suis) and verified by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis with Coomassie stain. All 
fractions containing PlySs2 were pooled and stored at -80°C. For in vivo tests requiring 
higher concentrations of 20 mg/ml, purified PlySs2 was dialyzed (into 15 mM NaCl, 5 
mM PB, pH 7.4), frozen to -80°C, lyophilized overnight, and resuspended in 
approximately one tenth of the initial volume before lyophilization. A bicinchoninic acid 
(BCA) assay (Sigma) was used to determine the protein concentration. 
2.1.4 Characterization 
2.1.4.1 Optimization 
The optimal biochemical conditions for PlySs2 enzymatic activity were screened 
using spectrophotometric analysis. Log-phase S. suis strain 7997 were adjusted with 
buffer to an OD600 of 0.8 to 1.0 in 96-well microtiter plates (Falcon). PlySs2, at 32 μg/ml, 
or control vehicle was added to each sample well. At room temperature, a Spectramax 
Plus 384 (Molecular Devices) took spectrophotometric readings (at λ = 600 nm, i.e., 
OD600) of each well every minute over an hour. The degree of S. suis turbidity reduction 
(OD600) in the test wells indicated the amount of lysin activity. The pH-dependence of 
the enzyme was first addressed using two buffer sets with overlapping pH ranges, 
citrate/phosphate (4.6 – 8.0) and bis-Tris propane (7.0 – 9.7). Concentrations of NaCl, 
ethylenediaminetetraacetic acid (EDTA), and dithiothreitol (DTT) were also varied. 
2.1.4.2 Stability 
The thermal stability of PlySs2 was studied by pre-exposing the enzyme to 




minutes, 37°C for hours, 4°C for days, and -80°C for months. The activity of each aliquot 
against S. suis 7997 was determined spectrophotometrically as described above. PlySs2 




PlySs2 was identified in a prophage region of an S. suis serotype 2 strain 89/1591 
(the ORF was originally annotated in GenBank as SH3-type 5 domain protein, 
ZP_03625529 (Lucas 2004, Schmitz, Schuch, and Fischetti 2010, Schmitz 2011)). The 
putative PlySs2 lysin had the greatest homology of only 35% identity over 53% coverage 
with an E-value of <10-7 – this was to an S. suis surface antigen. E. coli transformed with 
pBAD24_PlySs2 (a plasmid for PlySs2 expression) were grown on S. suis overlay plates. 
The formation of clearing zones, or plaques, around these E. coli colonies confirmed 
successful cloning and soluble expression. 
According to a National Center for Biotechnology Information Basic Local 
Alignment Search Tool (BLAST) search, PlySs2 likely encodes an N-terminal CHAP 
catalytic domain (cysteine-histidine amidohydrolase/peptidase, PF05257) and a C-
terminal SH3-type 5 binding domain (PF08460) (Figure 2.1). By primary sequence, the 
PlySs2 CHAP domain is divergent from other database CHAP domains (Figure 2.2, 














Figure 2.1 PlySs2 amino acid sequence and structure. 
With a molecular mass of ~26 kD, PlySs2 contains an amine-terminal catalytic domain 
and a carboxy-terminal binding domain. (A) PlySs2 amino acid sequence. (B) The 













Figure 2.2 PlySs2 enzymatic domain alignment. 
(A) The CHAP domains of the streptococcal lysins PlySs2 and PlyC (subunit A, 
GenBank no. AAP42310) are aligned here. Amino-acid identities are indicated with 
underlying asterisks and highlighting. The positions of the presumptive catalytic residues 
(cysteine and histidine, for which the domain is named) are indicated with arrows. (B) 
The aligned catalytic domains of the staphylococcal lysins PlySs2 and ClyS. Adopted 





The aforementioned preparation led to a highly pure lysin preparation in just two 
chromatographic steps. With a predicted pI of 9.01, PlySs2 flowed directly through a 
DEAE column at pH 7.4 (Figure 2.3, lane 4) leaving the bulk of the contaminant proteins 
on the DEAE column (compare Figure 2.3, lanes 3 and 4). Following an ammonium 
sulfate-precipitation step, PlySs2 eluted cleanly both in the shoulder of the flow through 
peak of a CM column and in the 17 mM NaCl wash (see methods for details), being 
purified from proteins that rapidly flowed through the CM resin. The preparation yielded 
∼60 mg of protein per liter of E. coli culture at ~1.5 mg/ml with >99% purity (Figure 2.3, 
lane 6). The yield increased to ~150 mg per liter of E. coli culture at ~2.0 mg/ml with 
>90% purity when the CM column step was omitted (Figure 2.3, lane 5). All experiments 
were performed with this preparation. Concentrating PlySs2 via lyophilization and 
reconstitution generated a soluble solution of PlySs2 at ~20 mg/ml, which retained the 
concentration-adjusted activity of the lower concentration starting material. 
41 
Figure 2.3 PlySs2 corresponded to bands at ~26 kDa on SDS-PAGE. 
All PlySs2 purification samples were run on 4-12% Bis-Tris gels at 200 V for ~40 mins 
and stained with Coomassie. Lane 1: Whole cell lysate from E. coli. Lane 2: Supernatant 
from lysed E. coli. Lane 3: Pellet from lysed E. coli. Lane 4: The DEAE column flow 
through containing PlySs2. Lane 5: Resuspended pellet from 40% ammonium sulphate 
precipitation. Lane 6: A single band at ~26 kDa indicating the purity of PlySs2 after the 
CM column. Note: PlySs2 has a predicted molecular mass of ~26 kDa. 
~26 kDa →
Lane          . 






The optimal biochemical conditions for PlySs2 activity were determined by 
evaluating PlySs2 activity against log-phase pathogenic S. suis strain 7997 under 
different conditions. The S. suis cells were prepared for spectrophotometric analysis. The 
activity was determined by the degree of S. suis strain 7997 turbidity reduction (OD600) 
following the addition of PlySs2 at 32 μg/ml. PlySs2 activity was tested through a range 
of pH values to determine its optimum physiological buffering conditions. The lysin was 
most active in citrate/phosphate buffer at pH 8.0 (Figure 2.4A) and in bis-Tris propane 
buffer at pH 9.7 (Figure 2.4B). PlySs2 could be optimally active at higher pH levels, but 
those levels would not be physiologically relevant. In the acidic range, there was strong 
activity to pH 6.0. Unlike certain other lysins, salt did not augment PlySs2 activity 
(Figure 2.5). Conversely, DTT did not inhibit PlySs2 function (Figure 2.6). Treatment 













Figure 2.4 PlySs2 was found to have the most acute activity in basic 
pH levels. 
To test the optimal pH for PlySs2 activity, 32 μg/ml PlySs2 was mixed with log-phase S. 
suis 7997 suspended to a final OD600 of 1.0 in phosphate/citrate buffer (A) or bis-tris 
propane (B) at various pH levels. In controls (-), ddH2O replaced PlySs2. 








































































Figure 2.5 NaCl does not augment PlySs2 activity. 
Log-phase S. suis 7997 were centrifuged and resuspended in PB to OD600 ~1.0. To test 
the optimal salinity for PlySs2 activity, 32 μg/ml PlySs2 was mixed with S. suis strain 
7997 in phosphate buffer at different NaCl concentrations. PlySs2 is most active in the 
absence of NaCl. In controls (-), PB replaced PlySs2. Spectrophotometric readings were 
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Figure 2.6 Dithiothreitol (DTT) does not inhibit PlySs2 activity. 
Log-phase S. suis 7997 were centrifuged and resuspended in PB to OD600 ~1.0. PlySs2 
was incubated in 5 mM DTT at room temperature for 60 minutes. Incubated or 
unincubated PlySs2 was added at 32 μg/ml. In controls (-), PB replaced PlySs2. 

































Figure 2.7 Minimal ion depletion from EDTA inhibits PlySs2 activity. 
Log-phase S. suis 7997 were centrifuged and resuspended in PB to OD600 ~1.0. PlySs2 
was added at 32 μg/ml to cells with various concentrations of EDTA. In controls (-), PB 
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The activity of each PlySs2 aliquot incubated at different temperatures was tested 
(at 32 μg/ml) against S. suis strain 7997 and spectrophotometrically evaluated, as outlined 
above. When PlySs2 was incubated at different temperatures from 22°C – 85°C for 30 
min, its activity was principally unaffected until 60°C (Figure 2.8A). Activity was 
retained during incubation at 37°C for 24 hours, with activity starting to diminish after 48 
hours (Figure 2.8, B). There was no observable decrease in activity after 15 days at 4°C 
(Figure 2.8, C) or storage at -80°C for >7 months (Figure 2.8, D). The lysin also endured 
10 consecutive freeze-thaws cycles (-80°C to room temperature) without any observable 













Figure 2.8 PlySs2 is stable under a variety of conditions. 
PlySs2 was incubated:  (A)  for 30 minutes at various temperatures, then cooled;  (B)  at 
37°C for different increments of time;  (C)  at 4°C for different numbers of days;  (D)  at 
-80°C for different numbers of months. For each test, 32 μg/ml PlySs2 was added to S. 
suis 7997 cells at an OD600 of ~1.0. Spectrophotometric readings were taken at OD600 
































































































































Figure 2.9 PlySs2 is stable and active after ten, consecutive freeze-
thaws. 
Log-phase S. suis 7997 were centrifuged and resuspended in PB to OD600 ~1.0. PlySs2 
was taken from -80°C to room temperature and back to -80°C on subsequent days from 
Day 1 to Day 10. A sample from each day was added to cells at 32 μg/ml. In controls (-), 
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3 CHAPTER 3 – STREPTOCOCCUS SUIS SUSCEPTIBILITY 
3.1 MATERIALS AND METHODS 
3.1.1 Bacterial strains 
All S. suis strains were stored at -80°C (Table 3.1). The strains were grown in 
brain heart infusion (BHI) broth at 37°C for all tests. Luria Bertani (LB) broth was used 






Table 3.1 Strains used in the S. suis susceptibility study 
Species Serotype Strain ATCC Sourcea 
     Escherichia coli   TOP10    1 
Streptococcus suis 1 
 
  2 
Streptococcus suis 1 6112   2 
Streptococcus suis 1 6388   2 
Streptococcus suis 2 
 
  2 
Streptococcus suis 2 10   2 
Streptococcus suis 2 S735 43765  2 
Streptococcus suis 3 
 
  2 
Streptococcus suis 4 
 
  2 
Streptococcus suis 5 
 
  2 
Streptococcus suis 6 
 
  2 
Streptococcus suis 7 
 
  2 
Streptococcus suis 7 7197   2 
Streptococcus suis 7 7711   2 
Streptococcus suis 8 
 
  2 
Streptococcus suis 9 
 
  2 
Streptococcus suis 9 7997   2 
Streptococcus suis 9 8067   2 
Streptococcus suis 10 
 




Species Serotype Strain ATCC Sourcea 
     Streptococcus suis 11 
 
  2 
Streptococcus suis 12 
 
  2 
Streptococcus suis 13 
 
  2 
Streptococcus suis 14 
 
  2 
 
a 1, The Rockefeller University Collection; 2, Jaap A. Wagenaar, Utrecht University, 




3.1.2 Lytic activity against S. suis 
Strains of bacteria were grown to log-phase at 37°C and brought to an optical 
density (OD600) of ~1.0 with 15 mM phosphate buffer (PB), pH 8.0 (buffer A) as 
measured in 96-well microtiter plates (Falcon). From these bacterial stocks, 245 μl were 
added to each well of a 96-well microtiter plate. In triplicate for every strain, each well 
received 5 μl of PlySs2 at 1.6 μg/μl (8 μg, thus a final concentration of 32 μg/ml). [In 
preliminary experiments, 32 μg/ml provided the best resolution in determining PlySs2 
activity.] Corresponding triplicate wells received 5 µl of 15 mM PB, pH 6.7 (buffer B) 
control vehicle. S. suis 7997 served as a positive control for each trial. As detailed above, 
spectrophotometric readings were taken of each well every minute over an hour. The 
degree of turbidity reduction indicated lysin activity. 
3.1.3 Bactericidal assay 
Log-phase bacteria were centrifuged and washed 1× in buffer A and adjusted to 
an OD600 of 0.1 (= 0.5 McFarland, ~108 CFU/ml) in buffer A with a SmartSpec™ Plus 
Spectrophotometer (Bio-Rad). A 100 µl aliquot of the cell suspension was distributed in 
96-well polypropylene microtiter plate (Costar). PlySs2, at 64 μg/ml, or buffer B control 
vehicle was added to wells in triplicate for each strain. Plates were sealed and shaken at 
37°C every minute for 1 hour. At this time, 10-fold serial dilutions of each well were 
plated on BHI agar and incubated at 37°C. Resultant colonies were enumerated after 18 
h. The bactericidal effect was calculated as the difference between vehicle-treated and 




3.1.4 MIC assay 
The protocol of Wiegand, et al. (Wiegand, Hilpert, and Hancock 2008) was used 
with adjustments to determine minimum inhibitory concentrations (MICs). Briefly, each 
strain was grown in BHI and adjusted to ~5 × 105 cells/ml in BHI and distributed into 4 
wells of a 96-well round bottom polystyrene microtiter plate. In each of two wells 
corresponding to each strain, either sterile-filtered lysin or control vehicle was added 
(Wiegand, Hilpert, and Hancock 2008). The lysin concentration varied from 0.5 – 1,024 
μg/ml PlySs2. The plates were then incubated for 18 h at 37°C. The MIC was the highest 
concentration of lysin that prevented the formation of a visible cell pellet (a measure of 
growth) on the bottom of the wells. The MICs were also colorimetrically confirmed by 
staining the bacteria in the wells with alamarBlue vital dye following the 
manufacturer’s protocol (Invitrogen). 
3.1.5 Resistance 
A published protocol to test the in vitro development of antibiotic-resistance was 
followed (Rouse et al. 2005, Pastagia et al. 2011, Gilmer et al. 2013). Briefly, S. suis was 
grown in the presence of doubling concentrations of PlySs2 over 8 days in BHI broth, 
and the PlySs2 MIC was tested daily to determine if resistance was acquired. On the first 
day, bacteria at ~5 × 108 CFU/ml were grown overnight at 37°C in 10 ml BHI containing 
1/32× the PlySs2 MIC for the given strain. On the second day, the culture was split into 
two equal portions. The cells of one aliquot were pelleted and resuspended in 10 ml fresh 
BHI media with double the concentration of PlySs2 (i.e., 1/16× the PlySs2 MIC on day 




PlySs2 was serially doubled from 1/32× the initial MIC (on day 1) to 4× the initial MIC 
(on day 8). 
 A sample of the second half of the aliquot was spread on BHI agar containing the 
PlySs2 MIC for that strain. After incubation at 37°C, 4 colonies were selected from the 
BHI agar plate to determine if a 4-fold increase in PlySs2 MIC was achieved for that 
strain, indicating the emergence of resistance. The protocol was repeated with gentamicin 
as an antibiotic resistance control for each S. suis strain, because S. suis strains develop 
resistance to gentamicin in vitro (Varela et al. 2013). 
3.2 RESULTS 
3.2.1 Lytic activity against S. suis 
Purified PlySs2 was tested against 22 strains representing 8 serotypes of S. suis to 
assess its range of lytic activity. Over 30 minutes, 14 of 22 strains were reduced to an 
OD600 ratio of ≤0.2 from a starting OD600 of ~1.0 (Figure 3.1). Readings taken after 60 
minutes showed the same relative reduction in OD600 (Figure 3.2). This group of PlySs2-
sensitive S. suis strains included the type strain S735, and the pathogenic strains 10 and 
7997. The reduction in OD600 ratio of other S. suis strains was reduced to ≤0.6. Serotype 








Figure 3.1 PlySs2 lysed almost all strains of S. suis over 30 minutes. 
Bacteria in logarithmic growth were exposed to 32 μg/ml PlySs2 for 30 minutes in PB 
(for 60-minute readings, see Figure 3.2). The activity was measured by OD600 reduction. 
To normalize and combine values from multiple tests, the final OD600 of the treated 
samples was divided by the final OD600 of the untreated samples. An OD600 ratio of 1.0 
indicates no lysis, while an OD600 ratio of ~0.02 indicates complete lysis. 
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Figure 3.2 PlySs2 lysed almost all strains of S. suis over 60 minutes. 
Bacteria in logarithmic growth were exposed to 32 μg/ml PlySs2 for 60 minutes in PB 
(for 30-minute readings, see Figure 3.1). The activity was measured by OD600 reduction. 
To normalize and combine values from multiple tests, the final OD600 of the treated 
samples was divided by the final OD600 of the untreated samples. An OD600 ratio of 1.0 
indicates no lysis, while an OD600 ratio of ~0.02 indicates complete lysis. 
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S. suis strains S735 and 7997 were also tested in a time-dependent lytic assay at 
various PlySs2 dosages (Figure 3.3 and Figure 3.4), showing a significant drop in OD600 
at >4 µg/ml for both strains. These time-dependent lytic assay results led us to use 32 







Figure 3.3 S. suis strain S735 exposed to various concentrations of 
PlySs2. 
S. suis strain S735 is sensitive to concentrations as low as 0.5 µg/ml PlySs2. S. suis strain 
S735 in logarithmic growth was exposed to various concentrations of PlySs2 ranging 

































Figure 3.4 S. suis strain 7997 exposed to various concentrations of 
PlySs2. 
S. suis strain 7997 is sensitive to concentrations as low as 1.0 µg/ml PlySs2. S. suis strain 
7997 in logarithmic growth was exposed to various concentrations of PlySs2 ranging 
































3.2.2 Bactericidal assay 
The lethal effect of PlySs2 was quantified for a select set of S. suis serotypes and 
strains. After 60 minutes of exposure to 64 μg/ml of PlySs2, all S. suis strains were 
reduced by 5-6 logs, except serotype 5 (~2-logs) (Figure 3.5). The relative lethal effect 
from one strain to another correlated with the lytic activity reported above. Strain 7197 
was an outlier in that it was reduced by ~5.5 logs in the bactericidal assay, but was only 






Figure 3.5 PlySs2 was bactericidal to nearly all strains of S. suis. 
Bacteria were grown to log-phase. After exposure to 64 µg/ml PlySs2 in buffer A for 60 
min in 96-well plates, bacteria were serially diluted and plated to BHI agar for CFU 
enumeration. The CFU numbers of most S. suis strains dropped by 5 to 6 logs after 
PlySs2 treatment including the type strain S735 and the pathogenic strains 10 and 7997. 
Log fold kill was calculated as -log[(# cells surviving test condition)/(# cells surviving 
















































































3.2.3 MIC assay 
The MIC of PlySs2 against these serotypes also qualitatively correlated with the 
lytic and bactericidal assays. The PlySs2 MIC ranged from 32 to 512 μg/ml for all 
PlySs2-sensitive strains. As expected, from earlier data, serotype 12 was not inhibited at 






Table 3.2 The MIC of PlySs2 for S. suis serotypes and strainsa 
Species Serotype Strain MIC (μg/ml) 
S. suis 




7 7197 128 




1 6112 256 










S. pyogenes M1 MGAS 5005 128 
 
a Bacteria were examined for growth at each concentration of PlySs2 from 0.5 - 1,024 
μg/ml. The lowest concentration preventing growth is the PlySs2 MIC (column 4) for 
each strain (columns 2 and 3) of each species (column 1). Consistent with other tests, S. 
suis type strain S735 registered a low MIC while there was a higher MIC observed for S. 
suis strain 7997. The MIC of PlySs2 for S. suis serotype 12 was above the assay 
parameters. The previously published PlySs2 MICs for S. aureus and S. pyogenes are 





According to an established protocol (Rouse et al. 2005, Pastagia et al. 
2011, Gilmer et al. 2013), both S. suis strains S735 and 7997 were challenged with 
incrementally doubling concentrations of PlySs2 to determine if they would develop 
resistance. Neither strain developed PlySs2 resistance – defined as exhibiting a >4× 
increase from the original PlySs2 MIC for each strain (Figure 3.6). Using the antibiotic 
gentamicin in the same procedure led to both S. suis strains S735 and 7997 developing 







Figure 3.6 S. suis 7997 and S735 did not develop resistance to PlySs2 
in vitro. 
S. suis S735 and S. suis 7997 grew in media containing 1/32× (3.13%) to 4× (400%) the 
MIC of PlySs2 or gentamicin over 8 days. Comparing the MICs of PlySs2 after each day 
to the initial MIC of PlySs2 for each strain determined resistance. Neither developed 
resistance to PlySs2. Both S. suis strain S735 and S. suis strain 7997 developed resistance 
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S. suis 7997 - Gentamicin
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4 CHAPTER 4 – BROAD GRAM-POSITIVE SUSCEPTIBILITY 
4.1 MATERIALS AND METHODS 
4.1.1 Bacterial strains 
All strains were stored at -80°C (Table 1.1). Staphylococcus, Streptococcus, 
Listeria, Enterococcus, Pseudomonas, Bacillus strains were cultivated in brain heart 
infusion (BHI) broth unless substituted with Mueller Hinton (MH) medium during the 
minimum inhibitory concentration (MIC) determination below. Lactobacillus strains 
were cultivated in de Man, Rogosa and Sharpe (MRS) broth (Sigma). Escherichia coli 
were grown in Luria Bertani (LB) broth. All media were acquired from Becton, 
Dickinson, and Company (Sparks, MD), unless otherwise stated. Bacteria were 




Table 4.1 Strains used in this study 
Organism Serotype Strain ATCC Sourcea Notes 
      Bacillus anthracis  
 
Δ Sterne   1   
Bacillus cereus 
 
14579   1   
Bacillus subtilis  
 
SL4   1   
Bacillus thuringiensis  
 
HD-73   1   
Enterococcus faecalis 
 
V583   1   
Enterococcus faecium  
  
  1 EFSK-2 
Escherichia coli 
 
TOP10   1   
Group E streptococci  2 












4356 3   
Lactobacillus gasseri  
  












Organism Serotype Strain ATCC Sourcea Notes 
      Listeria monocytogenes 
 
HER 
1184   1   
Listeria monocytogenes 4b 
N3013   1   
Listeria monocytogenes 3b 
FSLJ 1   1   
Listeria monocytogenes 
  
  1 RS823 
Listeria monocytogenes 
  
  1 RS820 
Listeria monocytogenes 
 
HER1083   1 






















RN4220   1 
 Staphylococcus aureus 
 
Newman   5 









1707  2 




192   1 methicillin resistant 
Staphylococcus aureus 
  
  1 
methicillin resistant 
from patient DS 
Staphylococcus aureus 
  





  1 





Organism Serotype Strain ATCC Sourcea Notes 
      Staphylococcus aureus 
  
  1 










  5 TNK3 
Streptococcus 
agalactiae Type II 
 
















dysgalactiae equisimilis  
 










 Streptococcus gordonii 
  
10558 2 
 Streptococcus mutans 
 
U159   1 
 Streptococcus oralis 
 





Organism Serotype Strain ATCC Sourcea Notes 
      Streptococcus 
pneumoniae 9V 
DCC1335   1 
 Streptococcus 
pneumoniae 6 
DCC1850   1 
 Streptococcus 
pneumoniae 15 








  1 mutant Lyt 4-4 
Streptococcus pyogenes M6 
D471   1 
 Streptococcus pyogenes M-neg 
D471   1 mutant JRS75 
Streptococcus pyogenes M6 MGAS 
10394 BAA-946  2 
 Streptococcus pyogenes M49 
NZ131   7 
 Streptococcus pyogenes M4 
SmR   1 
streptomycin resistant 
- mucoid 
Streptococcus pyogenes M3 MGAS 
315 BAA-595 2 
 Streptococcus pyogenes M18 MGAS 
8232 BAA-572  2 
 Streptococcus pyogenes M1 
CEM1ΔΦ   1 
mucoid – mouse 
passaged 
Streptococcus pyogenes M1 
CEM1ΔΦ   1 
 Streptococcus pyogenes M1 
SF370   1 





Organism Serotype Strain ATCC Sourcea Notes 
      Streptococcus pyogenes M1 
SF370   7 
 Streptococcus pyogenes M1 MGAS 
5005 BAA-947  2 
 Streptococcus rattus  
 





 Streptococcus sobrinus  
 
6715   1 
 Streptococcus suis 9 
7997   8 
  
a 1, The Rockefeller University Collection; 2, ATCC; 3, ContraFect Corporation, 
Yonkers, NY; 4, Alexander Tomasz, The Rockefeller University; 5, Olaf Schneewind, 
University of Chicago, Chicago, IL; 6, Barry Kreiswirth, Public Health Research 
Institute, New Jersey, NJ; 7, Joseph Ferretti, University of Oklahoma Health Science 





4.1.2 Lytic activity 
Log-phase bacteria were adjusted with buffer A to an OD600 of 0.8 to 1.0 in 96-
well microtiter plates (Falcon). PlySs2, at 32 μg/ml, or buffer B control vehicle was 
added to each sample well. In each run, S. suis 7997 was included as a positive control. 
Spectrophotometric readings (OD600) of each well were taken by a Spectramax Plus 384 
(Molecular Devices) every minute over 60 minutes at room temperature. Lysin activity 
was gauged by the degree of turbidity reduction (OD600) following enzyme addition. 
4.1.3 Bactericidal assay 
Log-phase bacteria were resuspended in buffer A to an OD600 of 0.1 (= 0.5 
McFarland, ~108 CFU/ml) and aliquoted into wells of a polypropylene microtiter plate 
(Costar). Actual inoculum titers for each experiment were derived from plating serial 
dilutions of each inoculum. For each organism, buffer B control vehicle or PlySs2 was 
added at 128 μg/ml to wells in triplicate. Plates were sealed and incubated at 37°C with 
agitation every 5 minutes for 1 hour. After incubation, cells were serially diluted in 10-
fold increments and plated on BHI agar. Death (log fold kill) was calculated as -
log[(CFUs in the test condition) ÷ (CFUs in the control condition)]. 
4.1.4 MIC assay 
The protocol from Wiegand, et al. was followed to determine MICs, with 
adjustments as detailed below (Wiegand, Hilpert, and Hancock 2008). Briefly, a final 
suspension of ~5 × 105 cells/ml in MHB (or BHI for S. pyogenes) plus sterile-filtered 
lysin or control vehicle was distributed within a 96-well microtiter plate in triplicate 
(Wiegand, Hilpert, and Hancock 2008). Cells were challenged with 0.5 – 1,024 μg/ml 




bottom of rounded polysterene plate wells; they were corroborated colorimetrically with 
alamarBlue vital dye (Invitrogen) following the manufacturer’s protocol. 
4.1.5 Resistance 
According to an established protocol for the in vitro development of mupirocin-
resistance (Rouse et al. 2005, Pastagia et al. 2011), S. aureus CA-MRSA MW2, S. aureus 
MSSA 8325, and S. pyogenes MGAS 5005 were grown in the presence of PlySs2 in 
liquid culture. Initially, bacterial cells at 5 × 108 CFU/ml were grown overnight in the 
presence of 1/32× the MIC of PlySs2 against each strain (37°C, BHI broth for S. 
pyogenes with cap secured during gentle shaking, MHB broth for S. aureus with 220 rpm 
aeration). The cells were pelleted by centrifugation for 10 min at 900 rcf and sub-divided 
into two aliquots. 
 One aliquot was diluted 10-fold into fresh MHB media with double the 
concentration of PlySs2; a portion of the other was spread onto the surface of MHA agar 
containing the PlySs2 MIC for that species. The MIC of 4 resultant colonies was 
recalculated by microdilution for each serial passage, as described above (Wiegand, 
Hilpert, and Hancock 2008). This was done to determine if a resistant clone had emerged 
(defined as a 4-fold increase in MIC). The above procedure was repeated over an 8-day 
period, and the concentration of PlySs2 in the liquid culture was serially doubled from 
1/32× to 4× the original MIC. This process was also conducted with mupirocin for each 
MRSA strain, to serve as an antibiotic resistance positive control. 
4.1.6 PlySs2 catalytic domain lytic assay 
The PlySs2 catalytic domain sequence (PlySs2-CD, ~0.49 kb), containing some 




vector was transformed into TOP10 E. coli (Invitrogen). For purification, E. coli cells 
induced to express pBAD24_PlySs2-CD were pelleted and re-suspended in 20 mM PB, 
pH 7.4 (buffer D). EDTA-free protease inhibitor tablets were added before homogenizing 
the cells, which were subsequently spun at 16,000 rpm for 60 min. The volume was 
adjusted with buffer D to raise pH. 
The soluble lysate was run through a CM Sepharose® column equilibrated to 
buffer D. The flow through containing PlySs2-CD was collected. This was dialyzed 
overnight at 4ºC into 20 mM glycine-NaOH, pH 9.3 (buffer E). This material was run 
over on Mono Q column equilibrated to buffer E. The material was eluted gradually from 
1-100 mM NaCl, buffer E. This was repeated with elution by 30-100 mM NaCl, buffer E. 
Pure fractions dialyzed into buffer D and pooled. Concentration was confirmed to be 1.7 
mg/ml. 
Following the aforementioned protocol for lytic assay (page 59), log-phase S. suis 
strain 7997 cells were exposed to full length PlySs2 (PlySs2-FL) at 32 µg/ml, and 
PlySs2-CD at 850 µg/ml. As before, the degree of turbidity reduction (OD600) in the test 
wells indicated the degree of lysin activity. 
4.1.7 Fluorescent binding assay 
The PlySs2 binding domain sequence (PlySs2-BD, ~0.26 kb) was cloned from S. 
suis strain 89/1591 with the forward primer (containing NheI site, underlined) 
AATGCTAGCATGCGTTCCTATCGCGAGAC, and the reverse primer (containing 
HindIII site, underlined) CCTAAGCTTCTTTTCACAAATCATAATCCCCAG. This 
was cloned into the pBAD24 vector and transformed into TOP10 E. coli (Invitrogen). 




E. coli cells induced to express pBAD24_PlySs2-BD were pelleted and re-
suspended them in 20 mM PB, pH 7.4 (buffer D). EDTA-free protease inhibitor tablets 
were added before homogenizing the cells, which were subsequently spun at 15,000 rpm 
for 80 min. The pH was reduced by adding 30 mM PB, pH 6.0. The lysate was run over a 
CM Sepharose® FF column where it eluted at 250 mM NaCl, buffer D. The pure 
fractions were pooled and dialysed overnight in 4 l of buffer D. A BCA protein assay 
(Sigma) confirmed the concentration to be 8.9 mg/ml. 
 This PlySs2-BD was labeled with AlexaFluor 488 as per the manufacturer’s 
instructions (Becton, Dickinson and Company – Sparks, MD). Subject strains were 
grown overnight in BHI at 37°C, and subsequently pelleted and resuspended in PBS to 
OD600 = 0.1. Of this dilution, 1 ml was pelleted and resuspended in 200 μl of 2% 
paraformaldehyde in PBS for 30 minutes.  
After washing with PBS, pellets were resuspended in 500 μl PBS + 5% blocking 
solution for 1 hour to which 500 μl PBS + 0.5 μl labeled PlySs2-BD was added for 
another hour. After three washes with PBS, pellets were resuspended in 50 μl PBS. Cells 
(5 μl) were then pipetted onto a slide sealed with a cover slip. Fluorescence photographed 
on an Eclipse E400 microscope (Nikon) using the QCapture Pro version 5.1 imaging 
software. Images displayed high, medium, and low intensity. 
4.2 RESULTS 
4.2.1 Lytic activity 
Purified PlySs2 was tested against a wide range of bacterial species and strains to 
determine the range of lytic activity. Starting at an OD600 of ~1.0, all tested strains of S. 




and lysostaphin – were reduced to an OD600 ratio ≤ 0.3 after lysis by PlySs2 over 30 
minutes of exposure (Figure 4.1). Readings were also taken after 60 minutes (Figure 4.2). 
The OD600 ratio of other staphylococci, including Staphylococcus simulans and 











Figure 4.1 PlySs2 displayed activity against various species. 
PlySs2 displayed activity against various species. Multiple strains of staphylococci 
(including MRSA, MSSA, and VISA), streptococci, enterococci, Listeria, bacilli, and 
lactobacilli were tested for susceptibility to PlySs2 activity. Escherichia and 
Pseudomonas were tested as Gram-negative controls. Log-phase cultures were exposed 
to 32 µg/ml PlySs2 for 30 min in PB (for 60-min readings) (see also Figure 4.2). The 
final OD600 of the treated samples was divided by the final OD600 of the untreated 















Figure 4.2 PlySs2 displayed activity against various species over 60 
minutes. 
Multiple strains of staphylococci (including MRSA, MSSA, and VISA), streptococci, 
enterococci, Listeria, bacilli, and lactobacilli were tested for susceptibility to PlySs2 
activity. Escherichia and Pseudomonas were tested as Gram-negative controls. Log-
phase cultures were exposed to 32 μg/ml PlySs2 for 60 minutes in PB. The final OD600  of 
the treated samples was divided by the final OD600 of the untreated samples to generate 







With streptococci, PlySs2 lysed most of the tested M-protein serotypes of S. 
pyogenes, including M1, M3, M4, M6, M18, M49, an M-negative variant, as well as 
unencapsulated and highly encapsulated strains, decreasing their OD600 ratio to ≤ 0.4. 
PlySs2 also exhibited strong lytic activity against S. suis, Streptococcus equi 
zooepidemicus, Streptococcus equi, S. agalactiae Type II (encapsulated), and S. 
agalactiae 090R. The pathogenic Streptococcus sanguinis, and groups G and E 
streptococci were moderately sensitive to PlySs2. Streptococcus mutans, group C 
streptococci, Streptococcus oralis, Streptococcus rattus, and Streptococcus sobrinus were 
only reduced to an OD600 ratio between 0.7 and 0.9. PlySs2 did not reduce the OD600 
ratio for any Streptococcus pneumoniae strains below 0.5. Streptococcus gordonii was 
the only commensal against which PlySs2 exhibited activity (Figures 4.1 and 4.2). 
 PlySs2 showed some activity against genera outside Staphylococcus and 
Streptococcus. While two strains of Listeria were sensitive to PlySs2, other strains were 
not. In the Enterococcus genus, which is associated with high levels of antibiotic 
resistance, E. faecalis was sensitive to PlySs2 (although less than staphylococci or 
streptococci), but E. faecium was not. No activity was seen against any of the different 
species of Bacilli, strains of lactobacilli, or Gram-negatives. 
4.2.2 Bactericidal assay 
PlySs2 was tested for log-fold killing of several species and strains of susceptible 
pathogenic organisms tested by OD600 decrease. At 128 μg/ml PlySs2 and 60 minutes 
exposure, the vancomycin-intermediate S. aureus (VISA) strain was only reduced by 2-




aureus, and S. pyogenes from ~3 to >6-logs (Figure 4.3). The negative control E. coli was 










Figure 4.3 PlySs2 was bactericidal across multiple species of bacteria. 
Log-phase bacteria were treated in 96-well plates with 128 µg/ml PlySs2 in buffer A for 
60 min, then serially diluted and plated onto BHI agar for CFU enumeration. The log kill 
was calculated by comparing the difference between vehicle-treated and PlySs2-treated 
CFU results. Of note, PlySs2 dramatically reduced S. agalactiae and L. monocytogenes. 




4.2.3 MIC Assay 
When the MIC of PlySs2 was tested against strains of S. aureus, S. pyogenes, L. 
monocytogenes, S. agalactiae, and E. coli, most of the values qualitatively correlated 
directly to the lytic and killing activity. MICs ranged from 8 to 256 μg/ml for all strains, 
except the VISA strain, which was not inhibited at >1,024 μg/ml (Table 4.2). The MIC of 
PlySs2 was relatively low for L. monocytogenes and S. aureus. S. pyogenes and S. 
agalactiae registered similar PlySs2 MICs. The negative control E. coli did not register a 




Table 4.2 The MIC of PlySs2 for various Gram-positive speciesa  
Species Strain MIC μg/ml 
Visual Colorimetric 
L. monocytogenes HER 1184 8 16 
HER 1083 8 16 
S. aureus MSSA 8325 16 16 
MRSA MW2 16 32 
LyrA 32 32 
VISA III 32 64 
GrAS SF370 128 128 
MGAS 5005 128 256 
GBS 090R 256 256 
type II 512 512 
E. coli Top10 >1,024 >1,024 
aAll MICs were evaluated visually for bacterial growth and with alamarBlue vital dye 
(colorimetrically) at concentrations from 0.5 to 1,024 µg/ml of PlySs2 for each strain of 
each species listed. There was a low MIC for MRSA MW2, as expected, and a higher 
MIC for GrAS strain MGAS 5005. The MIC of PlySs2 for the negative control, E. coli, 
was above the limits of the assay. For a reference, ClyS, LysK, and CHAPK lysins have 
registered MICs against S. aureus strains from 30 to 80 µg/ml (Pastagia et al. 





Using a published, standardized method for calculating resistance, both 
staphylococcal and streptococcal strains were analyzed for the development of resistance 
against PlySs2 by serial exposure to incrementally doubling concentrations of the lysin. 
Under these testing conditions, none of the S. aureus or S. pyogenes strains exposed to 
PlySs2 over 8 days developed resistance (defined as a 4-fold increase from the original 
MIC) (Figure 4.4). Following the same procedure, both S. aureus strains MW2 and 8325 









Figure 4.4 MRSA, MSSA, and GrAS did not acquire resistance to 
PlySs2 in vitro. 
MRSA strain MW2, MSSA strain 8325, and GrAS strain MGAS 5005 were exposed to 
1/32× to 4× the MIC of PlySs2 and mupirocin (S. aureus strains) over 8 days. The daily 
MICs of PlySs2 were compared to the starting MIC of PlySs2 for each strain of bacteria 
to ascertain resistance. None developed resistance to PlySs2. Both MW2 and 8325 















Day (% MIC exposure) 
MRSA MW2 - PlySs2
MRSA MW2 - Mupirocin
MSSA 8325 - PlySs2
MSSA 8325 - Mupirocin




4.2.5 PlySs2 catalytic domain lytic assay 
The catalytic domain is much less effective at mediating lysis of S. suis strain 
7997 compared to the full length PlySs2 lysin. Therefore, we used 850 µg/ml in order to 
establish enough resolution within its activity profile among various species and strains. 
Nevertheless, at a high concentration, it is able to lyse certain strains similar to the effect 
of PlySs2-FL at 32 µg/ml. The specificity of PlySs2-CD at high concentrations is 
somewhat consistent with the specificity of PlySs2 at lower concentrations against most 








Figure 4.5 Lytic effect of PlySs2 Full Length VS Catalytic Domain  
Strains of staphylococci (including MRSA, MSSA, and VISA), streptococci, enterococci, 
Listeria, bacilli, and lactobacilli were tested for susceptibility to PlySs2-FL or PlySs2-CD 
activity. Escherichia was tested as a Gram-negative control. Log-phase cultures were 
exposed to lysin for 60 minutes in PB. The final OD600 of the treated samples was 
divided by the final OD600 of the untreated samples to generate the normalized values. 
Complete lysis registers a ratio of ~0.02. 
 




















PlySs2-FL (32 μg/ml) 




4.2.6 Fluorescent binding assay 
Cells were tested for binding fluorescent PlySs2-BD. Many species were tested, 
but only three are presented here as representative results. PlySs2-BD bound best to S. 
agalactiae type II, although PlySs2-FL has less activity against this strain than against S. 
pyogenes strain 5005 or S. suis strain 7997. 
There was little correlation between the species that PlySs2-BD bound and the in 
vitro activity of PlySs2-FL or PlySs2-CD. This may be attributed to each domain 
requiring the other to mediate their effect. Nevertheless, this preliminary study will 










Figure 4.6 PlySs2-BD Flurescence and comparison to PlySs2-CD 
activity. 
1 – S. suis strain 7997 
2 – S. pyogenes strain 5005 
3 – S. agalactiae type II [1× exposure time (left bottom); ½× (right bottom)] 
(A) This PlySs2-BD was labeled with AlexaFluor 488 as per the manufacturer’s 
instructions (Becton, Dickinson and Company – Sparks, MD). Subject strains were 
resuspended in 500 μl PBS + 5% blocking solution for 1 hour to which 500 μl PBS + 0.5 
μl labeled PlySs2-BD was added for another hour. Cells (5 μl) were pipetted onto a slide 
sealed with a cover slip. Fluorescence photographed on an Eclipse E400 microscope 
(Nikon) using the QCapture Pro version 5.1 imaging software. Scale bars, 1 µm. (B) 


















PlySs2-FL (32 μg/ml) 
PlySs2-CD (850 μg/ml) 
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5 CHAPTER 5 – IN VIVO MODELS 
5.1 MATERIALS AND METHODS 
5.1.1 Intranasal mucosa model 
5.1.1.1 S. suis colonization 
A nasal mucosal colonization model described by Seitz, M., et al. (Seitz et al. 
2012), was used to test the in vivo efficacy of PlySs2 to decolonize S. suis strain 7997. 
Each strain was made spontaneously resistant to 200 μg/ml streptomycin, through 
passage of bacteria in media containing increasing concentrations of antibiotic, to 
distinguish it from other organisms found in the murine nasal mucosa. Next, 4-week old 
female CD-1® mice were obtained from Charles River (Wilmington, MA). After a week 
of acclimation, mice were given water with 5 mg/ml streptomycin. After two days, mice 
were anesthetized and 12.5 μl of 1% acetic acid was delivered to each nostril. An hour 
later, mice were administered 10 μl (∼1 × 109 CFU) of mid log-phase (OD600 of ~0.5) 
bacteria in 50 mM PB, pH 7.4 (buffer C) in each nostril. An aliquot of each inoculation 
stock was serially diluted and plated to Columbia blood agar plates to confirm the actual 
bacterial inoculation titer. 
5.1.1.2 Treatment 
Twenty-four hours post-colonization, the animals were randomly divided into 4 
treatment groups. To each nostril, we delivered 10 μl of either:  buffer C alone (group 1), 
5 mg/ml PlySs2 in buffer C (group 2), 5 mg/ml gentamicin in buffer C (group 3), or a 
combination of 2.5 mg/ml PlySs2 and 2.5 mg/ml gentamicin in buffer C (group 4). 
Twenty-four hours after treatment, all mice were euthanized by CO2-inhalation. The 




sinuses, and vortexed in 500 μl of buffer C. Serial dilutions were then streaked on 5% 
sheep blood plates (containing 200 μg/ml streptomycin) and incubated at 37°C for final 
colony counts. All protocols in this in vivo study were approved by The Rockefeller 
University’s Institutional Animal Care and Use Committee. 
5.1.2 Mixed bacteremia model 
5.1.2.1 MRSA + GrAS Infection 
The Rockefeller University’s Institutional Animal Care and Use Committee 
approved all in vivo protocols. A systemic infection model described by Daniel, A. et al., 
was used to test for the in vivo efficacy of PlySs2 against multiple Gram-positive bacteria 
(Daniel et al. 2010). Briefly, 4-5 week old female FVB/NJ mice (weight range 15 to 20 g) 
were obtained from The Jackson Laboratory (Bar Harbor, ME). After a period of 
acclimation, mice were injected intraperitoneally (IP) with 0.5 ml of mid log-phase 
(OD600 of 0.5) bacteria diluted with 5% hog gastric mucin (Sigma) in saline. Bacterial 
suspensions contained ∼5 × 105 CFU/ml of MW2, a PVL toxin-encoding MRSA strain, 
∼1 × 107 of MGAS 5005, an M1 serotype of S. pyogenes that is virulent in humans and 
mice, or a simultaneous combination of both bacteria at the above concentrations for the 
mixed infection experiments. Actual bacterial inoculation titers were calculated by serial 
dilution and plating to Columbia blood agar plates for each experiment. 
5.1.2.2 Treatment 
 Mice became bacteremic within 1-3 hours and contained MRSA and/or S. 
pyogenes within multiple organs, including spleen, liver, kidney, and heart/blood 
(reference (Daniel et al. 2010), and unpublished observations). Three hours post-




were administered IP 0.5 ml of either 20 mM phosphate buffer, 2 mg/ml of the 
streptococcal-specific lysin PlyC (Nelson et al. 2006), 2 mg/ml of the staphylococcal-
specific lysin ClyS (Daniel et al. 2010), 2-4 mg/ml PlySs2, or a combination of 2 mg/ml 
PlyC and 2 mg/ml ClyS. A PlySs2 stock of 4 mg/ml was used for S. pyogenes-infected 
mice to increase survival over an initial 70% survival rate with treatment of 2 mg/ml of 
PlySs2 (data not shown). While this dosage was possible with PlySs2, it was above our 
obtainable PlyC or ClyS stock concentration at the time. 
 The survival rate for each experimental group was monitored every 12 hours for 
the first 24 hours, then every 24 hours up to 10 days post-infection. The data were 
statistically analyzed by Kaplan-Meier Survival curves with standard error, 95% 
confidence intervals, and significance (Log-rank / Mantel-Cox test) calculated using the 
Prism computer program (GraphPad Software; La Jolla, CA). 
5.2 RESULTS 
5.2.1 Intranasal mucosa decolonization 
To determine if the in vitro activity of PlySs2 against S. suis predicts its ability to 
remove S. suis colonizing the nasal passages in vivo, mice were intranasally colonized 
with S. suis strain 7997, and subsequently treated intranasally with a single dose of 
PlySs2 or buffer. The number of CFUs remaining in the nasal mucosa was determined by 
plating serial dilutions on blood agar. The results from multiple, separate experiments 
were combined and plotted (Figure 5.1). Relative to the buffer-treated control, the nasal 
mucosa of mice were decolonized of S. suis by >3 logs after gentamicin treatment, >4 











Figure 5.1 PlySs2 and gentamicin may act additively to reduce S. suis 
in vivo. 
PlySs2 removed S. suis from the murine intranasal mucosa. CD-1® mice were nasally 
colonized with the pathogenic S. suis strain 7997. Twenty-four hours after colonization, 
in each nostril, mice received 10 μl of either 50 mM PB, pH 7.4 (buffer C), 5 mg/ml 
PlySs2 in buffer C, 4 mg/ml gentamicin in buffer C, or a combination of 2.5 mg/ml 
PlySs2 and 2.5 mg/ml gentamicin in buffer C. S. suis CFU counts were calculated for the 












5.2.2 Mixed bacteremia protection 
To determine if the broad lytic activity of PlySs2 could provide in vivo protection 
from Gram-positive pathogens, mice were infected IP with either MRSA (MW2) or S. 
pyogenes (MGAS 5005) independently or simultaneously, and subsequently treated with 
lysin(s). The results from 4 separate experiments were combined and mouse survival data 






Figure 5.2 PlySs2 protected mice from mixed MRSA and GrAS 
infection. 
FVB/NJ mice were injected i.p. with 5% mucin containing the pathogen of interest. Three 
hours post-infection, mice received one i.p. injection of either 20 mM phosphate buffer 
(control) or lysin treatment. (A) Survival data for the MRSA infection. Mice were 
infected with -5 × 105 CFU of MRSA strain MW2 and treated with either 1 mg of ClyS, 1 
mg of PlyC, or 1 mg of PlySs2. (B) Survival data for the GrAS infection. Mice were 
infected with -1 × 107 GrAS strain MGAS 5005 and treated with either 1 mg of ClyS, 1 
mg of PlyC, or 2 mg of PlySs2. (C) Survival data for the mixed MRSA and GrAS 
infection. Mice were infected with a combination of both bacteria from the above 
inoculums at the same concentrations. Mice were treated with either 1 mg of ClyS, 1 mg 
of PlyC, a combination of 1 mg of ClyS plus 1 mg of PlyC, or 2 mg of PlySs2. In all tests 
(A to C), mice were monitored for survival over 10 days. The results from 4 independent 
experiments were combined, and the data are plotted as a Kaplan-Meier survival curve; 
bars indicate standard errors. All the PlySs2 treatment groups (A to C) showed 
statistically significant differences (P < 0.0001) compared to the nonspecific single lysin 





















 Mice infected with MRSA alone could be protected from death with either PlySs2 
(89%; 16/18) or ClyS (86%; 24/28) lysins, but not the Streptococcus-specific PlyC (17%; 
2/12) (Figure 5.2A); while mice infected with S. pyogenes alone could only be protected 
with either PlySs2 (94%; 15/16) or PlyC (100%; 12/12), but not the Staphylococcus-
specific ClyS (0%; 0/12) (Figure 5.2B). Mice infected with S. pyogenes alone tended to 
succumb at a slower rate. All deaths from the MRSA infection occurred within the first 
two days; deaths from the S. pyogenes infection continued into the fourth day. In the first 
24 hours of infection: 4/18 (22%) control mice survived MRSA and 11/15 (73%) control 
mice survived S. pyogenes; with only 1/18 (6%) and 1/15 (7%) surviving to the end of the 
experiment, respectively. 
Likewise, only 1/23 (4%) of the buffer-treated control mice survived when 
simultaneously infected with both MRSA and S. pyogenes. In these mixed infection 
experiments, single-agent therapy with either ClyS (11%; 2/18) or PlyC (17%; 3/18) was 
also not significantly protective. While the mix infection animals treated with ClyS 
succumbed slower, with 14/16 dead by day 4, similar to mice infected with only S. 
pyogenes. However, mice could be protected from death with either a combination of 
ClyS and PlyC (80%; 16/20) or PlySs2 alone (92%; 22/24) over the 10-day course of the 
experiment (Figure 5.2C). Most of the PlySs2-treated mice survive the mixed infection 
yielding results comparable to, if not better than, the mice treated with both ClyS + PlyC 
at the same time. 
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6 CHAPTER 6 – DISCUSSION 
6.1 Lysin Characterization 
6.1.1 Identification 
Previous lysins have been identified from bacteriophage lysate, metagenomic 
screens, or shotgun-cloned phage DNA. After inspecting several S. suis genomic 
sequences, we found a putative open reading frame that resembled a phage lytic enzyme. 
This gene, PlySs2, was cloned, expressed, and found to have lytic activity against 
peptidoglycan.  
6.1.2 Purification and Stability 
PlySs2 is more tractable and stable than many previously reported lysins (Wang, 
Sun, and Lu 2009, Daniel et al. 2010, Nelson et al. 2006). PlySs2 preparation is relatively 
straightforward, yielding very pure, high yields of product in just a few steps. It remains 
soluble in concentrations exceeding 20 mg/ml (data not shown), and can be subjected to 
high or low temperatures for prolonged periods with little affect on its activity, even 
when repeatedly freeze-thawed. These features support PlySs2 as a suitable lysin for 
further development. 
Biochemical experiments analyzing the in vitro activity of PlySs2 showed that 
DTT had no effect on PlySs2 activity. This indicates that: [1] the lysin does not form 
dimers via disulfide bridges, and [2] recombinant PlySs2 folded properly – LySMP 
requires reducing agents (Wang, Sun, and Lu 2009). The lysins may differ in this 
requirement, because they vary in cysteine residues – LySMP has five, while PlySs2 has 
just one. Alternatively, the EDTA-induced inhibition of PlySs2 suggests that it may rely 




6.1.3 Catalytic Domain 
The PlySs2 catalytic domain is less lytic than the full-length protein, but still 
retains specificity. We had to use a much greater concentration of PlySs2-CD compared 
to PlySs2-FL, to mediate lysis. Nonetheless, our results suggest that a degree of 
specificity lies in the catalytic domain alone. Other phage lysins have CHAP domains 
(Nelson et al. 2006, Baker et al. 2006, Daniel et al. 2010, Becker et al. 2009, Donovan et 
al. 2006), but PlySs2 has a distinct primary sequence from other database CHAP domains 
(all pairwise E-values >10-15) (Schmitz 2011). In Figure 2.2, the CHAP domain of PlySs2 
is aligned to PlyC with little identity (28% sequence identity, E-value = 10-8) (Nelson et 
al. 2006). This indicates that there are novel features in the PlySs2 catalytic domain that 
may influence the lysins specificity, but the target is currently unknown. 
CHAP domains may act as alanine-amidases (Nelson, Loomis, and Fischetti 
2001) or cross-bridge endopeptidases (Daniel et al. 2010). Further, some strains of S. suis 
have no cross-bridge while others do (Kilpperbalz and Schleifer 1987). Therefore, while 
the PlySs2 CHAP domain mediates the catalytic activity of PlySs2, it probably does not 
confer the entire specificity of the enzyme. Going forward, the active site will need to be 
determined, possibly via the novel method involving mass spectrometry employed with 
the newly identified, anti-streptococcal lysin PlyPy (Lood et al. 2014). 
6.1.4 Binding Domain 
The promiscuity of PlySs2 casts even more uncertainty on the target for this 
binding domain. The cross-bridge varies greatly across all PlySs2-susceptible specimens, 
so it is an unlikely target for the PlySs2 binding domain. These cross-bridges can acquire 




lysostaphin-sensitive and lysostaphin-resistant (LyrA) S. aureus strains. Accordingly, 
experiments are in progress to determine the binding and cleavage substrates for PlySs2. 
In our work studying the binding domain, we’ve found that it differentially binds 
species and even strains of the same species. While the activity of the binding domain 
does not seem to correlate with that of the full-length enzyme (again suggesting some 
specificity attributed to the catalytic domain), the binding domain of PlySs2 does seems 
to contribute to its unique activity profile. Previous phage lysin binding domains have 
been shown in general to determine lysin specificity (Hermoso et al. 2003, Grundling and 
Schneewind 2006). As shown, PlySs2 has an SH3b domain, which has been shown to 
increase endolysin lytic domain activity against staphylococci and streptococci (Donovan 
et al. 2006). SH3 domains are commonly seen in viral and bacterial cell wall-binding 
proteins, although the exact molecular target remains unknown (Xu et al. 2009). SH3b 
(bacterial homologues of SH3 domains) have been shown to bind metals and 
polypeptides (Pohl, Holmes, and Hol 1999, Wylie et al. 2005). As such, an SH3b domain 
of a B. cereus endopeptidase has been shown to bind the free amino group of the N-
terminal alanine in the stem peptide of the peptidoglycan (Xu et al. 2010). The ubiquity 
of this amino acid domain in peptidoglycans, suggests this amine could also be the 
substrate for the broad binding of the PlySs2 SH3b domain. 
6.2 S. suis susceptibility to PlySs2 
6.2.1 Lytic activity 
The majority of examined S. suis strains were very sensitive to the PlySs2 lysin as 
seen in lytic, bactericidal, and MIC assays. As such, PlySs2 could alter the way 




S735 nor the pathogenic S. suis strain 7997 developed resistance to PlySs2 when tested in 
vitro. A critical strength of PlySs2 is its wider specificity to a subset of Gram-positive 
bacterial pathogens, including S. suis (Gilmer et al. 2013), enabling broader protection 
from these organisms.  
There was consistency among the lytic, bactericidal, and MIC assays; each 
returned qualitatively correlative results – i.e., the most sensitive strains displayed high 
susceptibility in each test. The MIC of other S. suis lysins have not been published, but 
the PlySs2 MIC for S. aureus and S. pyogenes are similar to those of S. suis (Table 1, 
(Gilmer et al. 2013)). For many clinical strains of S. suis, the MICs of ampicillin, 
amoxicillin, ciprofloxacin, kanamycin, and rifampin is >640 μg/ml (Meng et al. 2011). 
This MIC level is higher than the PlySs2 MIC against all but one of the S. suis strains we 
tested (Table 1). On a molar basis, with the molecular weight of PlySs2 being 26,060 
g/mol, PlySs2 is several-fold more effective than antibiotics, which are usually ≤500 
g/mol (e.g., gentamicin ~478 g/mol). 
6.2.2 Implications of lytic activity 
PlySs2 could have promise in vivo against nearly all S. suis strains (save serotype 
12 – the only tested serotype that was not moderately susceptible to PlySs2) (Figure 3.1). 
The reason for this innate resistance is unknown at this time, but could be due to 
differences in the cell wall that prevent lysin access to the peptidoglycan. Modifications 
in the binding or catalytic substrates of the S. suis serotype 12 cell wall could also nullify 
PlySs2 activity. Nevertheless, all other strains including both pathogenic strains 10 and 
7997 were highly sensitive to PlySs2. As with some of the S. suis strains, PlySs2 was 




vitro (Gilmer et al. 2013). However, despite this lower efficiency against S. pyogenes 
5005, PlySs2 is able to protect mice from bacteremia by strain MGAS 5005, suggesting 
that PlySs2 could also be protective in vivo to moderately susceptible S. suis strains 
(Gilmer et al. 2013). Alternative reasons for the various levels of activity among S. suis 
strains could also be due to a variety of differences including, but not limited to: i) 
encapsulation ii) cell wall thickness iii) catalytic domain specificity and iv) expression of 
the cell wall receptor to which the binding domain attaches.  
6.3 Broad Gram-positive susceptibility 
6.3.1 Lysin specificity 
PlySs2, has demonstrated broad lytic activity against multiple Gram-positive 
pathogens, including S. pyogenes and S. aureus, in vitro. Most previously characterized 
lysins, by contrast, demonstrate activity against a narrow spectrum of species. Contrary to 
the broad activity of PlySs2, a noted strength of many lysins is their target-specificity. 
Antibiotics may kill commensal organisms along with target pathogens, potentially 
leading to adverse sequelae (e.g. diarrhea, or more serious Clostridium difficile 
complications) (Kuijper et al. 2006). By contrast, lysins might be used to treat a single 
pathogen without disrupting the normal bacterial flora (Fischetti 2008), although this 
specificity could admittedly be a limitation in treating multiple pathogens. Our results 
show it is possible that a single lysin like PlySs2 could be used to treat multiple Gram-
positive pathogens, leaving many other Gram-positive and all Gram-negative 
commensals unaffected. 
PlySs2 did not lyse any commensal lactobacilli and showed significant activity 




strains of bacilli. It is unlikely that PlySs2 could be used therapeutically for S. mutans, S. 
oralis, S. rattus, and S. sobrinus as well as some strains of S. pneumonia, because of its 
low activity against these pathogens. 
6.3.2 Broad PlySs2 lytic activity 
PlySs2 exhibits activity against members of two distinct phylogenetic orders: 
Bacillales (Staphylococcus, Listeria, et al.) and Lactobacillales (Streptococcus, 
Enterococcus, et al.). The peptidoglycan structures of these two orders are quite similar 
except for their cross-bridges, which vary widely in composition and length (Schleifer 
and Kandler 1972, Vollmer, Blanot, and de Pedro 2008). Phage lysins rarely act on both 
Bacillales and Lactobacillales (Loeffler, Nelson, and Fischetti 2001, Schuch, Nelson, and 
Fischetti 2002, O'Flaherty et al. 2005, Zimmer et al. 2002, Loessner et al. 1997, Daniel et 
al. 2010). Furthermore, other lysins usually retain greater activity against the species 
infected by the phage from which the lysin was cloned (Yoong et al. 2004, 2006), 
whereas PlySs2 demonstrated more activity against S. aureus than S. suis. The lack of 
activity against Gram-negatives like Escherichia coli is expected, because their outer-
membrane shields their peptidoglycan layer. 
Lysing only 2 of 6 listeria strains tested, PlySs2 activity against listeria was less 
determinate. The activity of PlySs2 against Staphylococcus simulans, Streptococcus equi 
zooepidemicus, Staphylococcus equi, S. suis provides further evidence that the substrate 
for the binding domain exists outside of the cross-bridge, because their cross-bridges vary 
(with some having no cross-bridge at all). The polysaccharide capsule around S. 
agalactiae enhances its virulence. Type II S. agalactiae has a thicker capsule than most, 




agalactiae strains with thinner capsules have been shown to be less virulent (Rubens et 
al. 1987, Wessels et al. 1989). Importantly, PlySs2 has comparable activity against S. 
agalactiae  with and without a capsule, Type II, and  090R respectively. 
6.3.2.1 S. aureus susceptibility to PlySs2 
All tested strains of S. aureus were highly susceptible to lysis by PlySs2 (Figure 
4.1), including strains resistant to methicillin, vancomycin, daptomycin, mupirocin, and 
lysostaphin. Its lytic activity against vancomycin-intermediate S. aureus (VISA) and 
Newman strains was somewhat less than its lytic activity against other staphylococcal 
strains. The reduced activity against the VISA strains could be the result of the thicker 
cell wall in these organisms (Sieradzki and Tomasz 2003), increasing the time necessary 
to result in lysis. The strong activity of PlySs2 against S. simulans and S. epidermidis 
supports its use to treat a wide array of other staphylococcal infections. 
6.3.2.2 Streptococcal susceptibility to PlySs2 
Many streptococci were susceptible to PlySs2 lysis in vitro. PlySs2 exhibited 
potent lytic activity against its native species, S. suis, as well as S. equi, S. equi 
zooepidemicus, and S. pyogenes. Of note, there was no difference in PlySs2 activity 
against unencapsulated or highly encapsulated variants of S. pyogenes. There are greater 
than 150 M types for S. pyogenes (Bessen et al. 2011). Remarkably, PlySs2 has activity 
against all the tested M-types. Moderate activity was observed against groups C, E, and G 
streptococci, suggesting in vivo experiments will be necessary to determine if PlySs2 
could be used to treat infections by these organisms. PlySs2 activity against S. sanguinis 
also indicates its potential to treat dental plaque. Further studies must investigate its 




Although the in vitro activity of PlySs2 is more robust against MRSA than S. 
pyogenes, our in vivo data demonstrates its efficacy as an effective therapeutic against 
each. This may be due to differences in the structure or composition of the S. aureus cell 
wall compared to that of S. pyogenes affecting substrate accessibility. It could also be a 
result of the pathogenesis of each species and how they interact with the murine host. 
6.3.3 Broad bactericidal activity against streptococci and staphylococci 
As with the activity against S. suis, we found that the bactericidal assays 
quantitatively confirm PlySs2’s ability to effectively kill strains that vary in drug 
resistance and encapsulation; with correlations between the lytic, bactericidal, and MIC 
assays. Thus, even though they were not tested, it is likely that pathogens that were found 
to be more sensitive to in vitro PlySs2 lysis than S. pyogenes MGAS 5005, may also be 
sensitive to PlySs2 in vivo. Of note, the MIC of PlySs2 against several S. aureus strains 
was less than or equal to the MICs of other staphylococcal lysins including ClyS, LysK, 
and CHAPK (Pastagia et al. 2011, Daniel et al. 2010, Fenton et al. 2011, Becker et al. 
2009). 
6.4 Absence of in vitro resistance to PlySs2 
6.4.1 No observable in vitro resistance to PlySs2 in S. suis 
Using the same conditions that led to gentamicin resistance, the pathogenic S. suis 
strain 7997 and the type strain S735 were unable to establish resistance to PlySs2. This 
result is consistent with other lysins, such as ClyS and PlyG (Schuch, Nelson, and 
Fischetti 2002, Pastagia et al. 2011). Antibiotic resistance may occur when bacteria either 
inactivate the drug or alter the target site. No molecule has been described to 




disparate bacterial species with either diverse peptidoglycan cross-bridge structures, or no 
cross-bridge at all (Robinson, Hardman, and Sloan 1979), the PlySs2 cleavage site is 
unlikely to be the cross-bridge, but a more common peptidoglycan structure. Since lysins 
have evolved to target essential cell wall structures (Fischetti 2008), it may be difficult 
for structural resistance to rapidly occur. 
6.4.2 No observable in vitro resistance to PlySs2 in MRSA or S. pyogenes 
All of the Gram-positive pathogens against which PlySs2 has activity have 
developed resistance against conventional antibiotics. Neither S. pyogenes nor MRSA 
were able to establish resistance to PlySs2 under conditions leading to mupirocin 
resistance. As mentioned, a PlySs2-susceptible pathogen may not easily alter the PlySs2 
peptidoglycan target. To date, the only known resistance to a lysin-like molecule involves 
the insertion of a serine residue into an S. aureus pentaglycine cross-bridge to establish 
resistance to lysostaphin (a non-phage endopeptidase from S. simulans). However, it is 
unlikely that PlySs2 is a canonical cross-bridge endopeptidase, because of its activity 
against disparate bacterial species with diverse cross-bridge structures (Robinson, 
Hardman, and Sloan 1979), which included lysostaphin-resistant staphylococci. 
6.5 Intranasal mucosa decolonization 
PlySs2 is one of the most effective lysins used to decolonize the murine intranasal 
mucosa of pathogenic bacteria (Cheng et al. 2005, Loeffler, Nelson, and Fischetti 
2001, Nelson, Loomis, and Fischetti 2001, Rashel et al. 2007, Schuch, Nelson, and 
Fischetti 2002, Daniel et al. 2010). It is also the first lysin tested in combination with an 





On a molar basis, our results show that PlySs2 can kill S. suis in vivo several-fold 
more effectively than gentamicin, without killing as broadly as gentamicin. During 
treatment of an S. suis infection with antibiotics, both commensal and pathogenic bacteria 
would be affected, causing deleterious sequelae in the treated individuals. However, 
PlySs2 used alone to treat an S. suis infections should have minimal effect on the normal 
bacterial flora. 
6.5.1 Lysin alone or with antibiotic 
Colonization by S. suis could be reduced by PlySs2 alone or in combination with 
gentamicin. An important finding in this thesis was that a single dose of PlySs2 could 
reduce the pathogenic S. suis strain 7997 from murine intranasal mucosa by >4 logs 
(Figure 5.1). This is significantly greater than the <3-log reduction of strain 7997 after 
treatment with gentamicin. PlySs2 + gentamicin resulted in a >5-log decrease in 
intranasal carriage of strain 7997 after a single dose, suggesting that such a combination 
can be used together for increased effectiveness. This builds on previous studies reporting 
beneficial interactions between lysins and antibiotics – the first being the in vitro synergy 
of Cpl-1 with gentamicin and penicillin (Djurkovic, Loeffler, and Fischetti 2005). In vivo 
synergy has been reported between ClyS and oxacillin (Daniel et al. 2010), and recently 
also between PlySs2 and daptomycin, vancomycin, or oxacillin (Schuch et al. 2013). 
Other lysins have been shown to decolonize staphylococci, streptococci, or 
pneumococci in oral and nasal animal models (Cheng et al. 2005, Loeffler, Nelson, and 
Fischetti 2001, Nelson, Loomis, and Fischetti 2001, Rashel et al. 2007, Schuch, Nelson, 
and Fischetti 2002, Daniel et al. 2010); but these lysin decolonization models did not 




have developed resistance to mupirocin, the main anti-infective used for mucous 
membrane decolonization or carriage reduction of staphylococci (Hudson 1994). Our 
results indicate that lysins could be used in combination with antibiotics for mucosal 
decolonization, capitalizing on the strengths of both lysins (rapid, specific killing) and 
antibiotics (longer half life). 
6.5.2 Prophylaxis 
A pregnant sow carrying S. suis in her nasal mucosa may transmit the pathogen to 
her piglets (Clifton-Hadley 1984, Robertson and Blackmore 1989), resulting in fatal S. 
suis infections (Robertson et al. 1991, Amass, Wu, and Clark 1996, Torremorell, 
Calsamiglia, and Pijoan 1998, Cloutier et al. 2003, Swildens et al. 2007). PlySs2 could be 
used to prophylactically remove or significantly reduce S. suis from the nasal mucosa of 
the pregnant or nursing sow until her offspring are beyond the age of acute S. suis 
susceptibility. This could be done with a minimally invasive topical treatment, as shown 
with our murine model, as lysins can be active in both liquid and gel formulations 
(Pastagia et al. 2011, Gilmer et al. 2013). 
6.6 Mixed bacteremia protection 
No lysin has been used to clear a bacteremic infection in vivo by more than one 
pathogenic organism; to our knowledge mixed infections have not been previously tested. 
An important finding in this study was our ability to clear mixed MRSA and S. pyogenes 
bacteremic infections from 92% of mice with a single dose of PlySs2. This survival rate 





In a mixed infection, using either PlyC or ClyS alone eliminated only one of the 
infecting pathogens, resulting in death by the other; this death occurred within the same 
time frame and rate as the corresponding singly infected, non-treated controls, i.e., 
MRSA-infected animals died in 24 hours and S. pyogenes infected animals in 3 days. All 
three curves of the infection experiments (Figure 5.2A, B, and C) come from the same 
initial inoculums in 4 experiments, i.e. mixed infection experiments always paired with 
both types of single infection experiments to show that the single infection alone would 
kill animals if not treated properly. These results strongly support the idea that PlySs2 is 
curing the animals of their infection by simultaneously killing both pathogens. Further, 
stronger results may arise from increased or repeated dosage. 
6.6.1 Implications 
This study demonstrates that a combination of lysins (PlyC and ClyS) with 
different specificities could be used effectively to treat mixed infections (Figure 5.2C). 
The chimeric staphylococcal lysin ClyS, has been shown to clear MRSA from a murine 
model of septicemia (Daniel et al. 2010). To date, besides our work on PlySs2, no lysin 
has been shown to clear more than one organism from a septicemia infection, and none 
has cleared a mixed infection of any kind. 
Recent studies have indicated that secondary infections caused by colonizing 
MRSA, S. pyogenes, or S. pneumoniae have accounted for up to 90% of deaths from 
influenza pandemics (Morens, Taubenberger, and Fauci 2009, Brundage and Shanks 
2007, 2008, Hussell, Wissinger, and Goulding 2009). The same pathogens caused 
complications in nearly 30% of the 2010 H1N1 pandemic cases (2009). Prophylactic 




The moderate PlySs2 specificity for certain pathogens, and the lack of resistance 
in those pathogens qualifies PlySs2 for prophylactic usage. Mupirocin and polysporin are 
typically given to treat S. aureus on mucous membranes, but S. aureus can develop 
resistance to each (Hudson 1994). Lysins with specific activities against either 
staphylococci, streptococci, or pneumococci have each been shown to decolonize these 
pathogens in animal models of oral and nasal mucosal colonization (Cheng et al. 
2005, Loeffler, Nelson, and Fischetti 2001, Nelson, Loomis, and Fischetti 2001, Rashel et 
al. 2007, Schuch, Nelson, and Fischetti 2002, Daniel et al. 2010), however, a mixture of 
the three enzymes would need to be used to remove these pathogens. PlySs2 alone could 
be used to decolonize susceptible populations of staphylococci, streptococci, and perhaps 
certain pneumococcal isolates during flu season to reduce the possibility of a secondary 
infection. 
Furthermore, PlySs2 may also serve as a viable treatment for other infections and 
diseases caused by S. aureus and/or S. pyogenes such as: scarlet fever, erysipelas, 
cellulitis, necrotizing fasciitis, endocarditis, bacteremia/sepsis, a variety of abscess and 
non-abscess forming SSTIs, and impetigo. It may also treat neonatal septicemia, because 
it displays more in vitro activity against S. agalactiae than it does against S. pyogenes 
5005 (Figure 4.1, Figure 4.3, Table 4.2). S. aureus and S. pyogenes cause diseases with 
similar pathologies and sites of infection in man. Clinicians are often unsure which 
organism is causing disease, which could be a mixed infection in severe trauma cases. 
PlySs2 would be a valuable tool in their repertoire to treat such cases. 
As a lysin, PlySs2 rapidly kills its target, far quicker than antibiotics. PlySs2 only 




must remain in contact with the bacteria for 1-3 hours before any effect is seen on 
bacterial viability is observed. This feature has enabled phage lysins to treat systemic 
infections in animal models (Loeffler, Nelson, and Fischetti 2001, Schuch, Nelson, and 
Fischetti 2002).  
6.6.2 PlySs2 applications 
One could also use PlySs2 to prophylactically clear human mucous membrane 
reservoirs of pathogenic bacteria resistant to antibiotics. Antibiotics are not used in this 
manner, because resistant bacteria could emerge. Penicillin can be used to treat S. 
pyogenes, which remains acutely sensitive; but if the impetigo is caused by MRSA, 
penicillin may be ineffective. If PlySs2 were used prophylactically and resulted in even a 
moderate drop in colonization of 10% or more, it could reduce the severity of this 
disease. 
 PlySs2 may treat primary infections and prophylactically decrease the likelihood 
of secondary infections. Given its rapid clearance of MRSA and S. pyogenes, PlySs2 
could be used in the case of complications. This would be especially necessary for high-
risk individuals, which are allergic to leading antibiotics, have been exposed to a series of 
antibiotics, or are immunocompromised (which leads to a higher rate of mortality from 
bacterial infection). In the septic mice, PlySs2 acted quickly enough that it could have an 
effect before being cleared from the animal. The results also indicate that PlySs2 remains 
active in blood. 
In humans, there are no known substances to which lysins bind. Neither 
antibodies formed by mice nor humans are able to inactivate lysins (Loeffler, Djurkovic, 




administered intraperitoneally, Cpl-1 (an anti-pneumococcal lysin) cured mice of 
pneumonia (Grandgirard et al. 2008, Witzenrath et al. 2009). This provides further in vivo 
evidence that lysins can act quickly and effectively at different sites from administration.  
6.7 Other tests 
 In this report, we show PlySs2 was effective against S. suis, MRSA, and GrAS in 
murine decolonization and bacteremia models. Other in vivo models have been executed 
using PlySs2. This includes a MRSA rat wound infection model, which we will publish 
soon. In the Appendix, we detail the preliminary work behind a set of swine S. suis 
colonization and infection experiments. Our collaborators at Novartis have also executed 
a rabbit MRSA endocarditis experiment, but there were technical issues, which 
obfuscated the results. Finally, there are multiple promising in vivo models currently 
underway, which were designed by ContraFect Corp. in an effort to enter Phase I trials 
with PlySs2 (termed “CF-301” by ContraFect Corp.). 
6.8 Importance 
In summary, we have discovered a novel approach for treatment and prophylaxis 
of S. suis infection and/or colonization, with remarkable activity against all but one tested 
strain of S. suis. Pregnant sows treated prophylactically with PlySs2 prior to delivery, and 
S. suis piglet infections treated with PlySs2 alone or in combination with antibiotic could 
help control this disease on farms. Since we found that neither S. suis strain 7997 nor 
S735 developed resistance to PlySs2 in vitro, PlySs2 could be developed as a vital 
addition to the current approaches controlling S. suis spread in pigs, and zoonotic 




While pursuing a novel treatment for S. suis infection, we discovered a lysin with 
broad lytic activity against strains of MRSA, VISA, S. suis, Listeria, S. simulans, S. equi 
zooepidemicus, S. equi, S. agalactiae, S. pyogenes, S. sanguinis, S. gordonii, group G 
streptococci, group E streptococci, E. faecalis, and S. pneumoniae. PlySs2 was relatively 
simple to produce, tractable, and very stable. We have demonstrated here the ability of 
PlySs2 to protect mice with mixed infection by MRSA and S. pyogenes. Neither of these 
pathogens was observed to develop resistance to PlySs2 in vitro. PlySs2 could therefore 
become a vital addition to the armamentarium against multi-drug resistant S. aureus, S. 
pyogenes, and various other Gram-positive pathogens. 
PlySs2 represents a novel breakthrough in the field of bacteriophage lysin 
technology. It is now possible to envision other lysins with broad therapeutic activity 
retaining specificity to a subset of mostly pathogenic Gram-positives. For PlySs2, this 
novel capability possibly lies in the divergent PlySs2 CHAP domain, or SH3 binding 
domain. PlySs2 occupies a vital space in the spectrum between strict lysin specificity and 
unselective antibiotic activity. Ideally, a therapeutic should have activity against major 
pathogens without affecting commensals; this report of PlySs2 is the first to indicate that 






7 CHAPTER 7 – CONCLUSIONS 
Bacteriophages have evolved lysins to infect and destroy bacterial hosts over a 
billion years. Lysins provide a novel source of antimicrobials as antibiotic resistance 
expands. With technological advances, numerous lysins are being discovered. This study 
expands the lysin armamentarium with a vital addition and new applications. 
We have introduced one of the first lysins with in vivo efficacy against multiple, 
leading, human bacterial pathogens. This is the first indication that a lysin with activity 
against two pathogens could be used to treat a mixed or indistinguishable infection – 
rather than using a broad-spectrum antibiotic. This study reinforces the strength of lysin 
technology as none of the bacteria treated in vivo developed lysin resistance in vitro. 
The results indicate that lysins could be used combinatorially or with antibiotics, 
capitalizing on the strengths of both lysins and antibiotics. The latter approach could 
reduce the rate of antibiotic resistance, extending antibiotic utility. Having used two 
lysins to clear a mixed infection, we can now envision the application of a lysin 
armamentarium. A repertoire of lysins targeted to specific pathogens could be used for 
each pathogen independently, or in concert. 
Many challenges remain. At this time, no lysins have been approved by the FDA 
for human therapeutic use. Furthermore, there are no reports describing the clinical 
development of a phage lysin, however these activities have begun for some enzymes. 
Because of the narrow spectrum of activity for some lysins, diagnostics for rapid 
pathogen identification would be useful for selecting the therapeutically relevant lysin. 
Nevertheless, the need for novel antimicrobials and advances in technology should 













8.1 PlySs2 minipig protection from S. suis 
8.1.1 BACKGROUND 
The first in vivo PlySs2 test included PlySs1 and occurred in minipigs. Prior to the 
discovery of PlySs2, Dr. Jonathan Schmitz discovered PlySs1 – a LySMP homologue – 
by screening the unsequenced genome of clinical S. suis strain 7711 (Schmitz 2011). 
After cloning and expression, PlySs1 was purified through ammonium sulphate 
precipitation and DEAE anion-exchange column chromatography. 
8.1.2 MATERIALS AND METHODS 
8.1.2.1 PlySs1 + PlySs2 preliminary drug interaction 
PlySs1 and PlySs2 were tested to determine whether they would have an 
antagonistic, additive, or synergistic effect on their respective activity against S. suis 
strain 7997. As in previous chapters, log-phase bacteria were adjusted with buffer A to an 
OD600 of 0.8 to 1.0 in 96-well microtiter plates (Falcon). PlySs1 at 8 or 16 µg/ml, PlySs2 
at 2 or 4 μg/ml, PlySs1 + PlySs2 (at 8 µg/ml and 2 µg/ml, respectively), or buffer B 
control vehicle was added to each sample well. Spectrophotometric readings (OD600) of 
each well were taken by a Spectramax Plus 384 (Molecular Devices) every minute over 
one hour at room temperature. Lysin activity was gauged by the degree of turbidity 
reduction (OD600) following enzyme addition. 
8.1.2.2 Minipig treatment 
To test PlySs1 and PlySs2 against S. suis in vivo, 22 minipigs were colonized with 




direct nasal inoculation. After 1 week, each group was separated into two equal 
subgroups. 
Twice daily, half of the contact-colonized, and half of the inoculation-colonized 
pigs were treated. These treatment subgroups received, both nasally and orally, 5 ml 
saline solutions containing 1,118 mg of PlySs1 and 430 mg of PlySs2 twice daily. A 
higher dose of PlySs1 was given, because PlySs1 has is less active against S. suis than 
PlySs2. The increased dose of PlySs1 compared to PlySs2 was inversely proportional to 
their different S. suis activity. The untreated subgroups received 5 ml saline solution 
nasally and orally twice daily. This fatal infection rate was tracked over two weeks. 
8.1.3 RESULTS 
8.1.3.1 PlySs1 + PlySs2 preliminary drug interaction 
PlySs1 and PlySs2 seem to have a synergistic effect on S. suis. When used at half 
the concentration together, they register a greater activity than either of them at double 
those respective concentrations. This suggests that their divergent structures confer 







Figure 8.1 PlySs1 + PlySs2 drug interaction. 
Log-phase S. suis 7997 were centrifuged and resuspended in PB to OD600 ~1.0. To test 
PlySs1 and PlySs2 interaction, 8 μg/ml PlySs1 and 2 µg/ml PlySs2 were mixed with S. 
suis strain 7997 in phosphate buffer. Tests were also run with 8-16 μg/ml PlySs1 and 2-4 
µg/ml PlySs2 alone to indicate whether PlySs1 + PlySs2 combined activity was merely 
additive or synergistic. In controls (-), PB replaced lysin. Spectrophotometric readings 


















Control (no lysin) 2 μg/ml PlySs2 
8 μg/ml PlySs1 16 μg/ml PlySs1 




8.1.3.2 Minipig treatment 
None of the contact inoculated pigs died over two weeks; neither in the control 
nor the test group. Of the minipigs directly inoculated with S. suis, 1/5 (20%) of the 








Figure 8.2 Pig deaths over two weeks. 
Minipigs were either inoculated with ~1×109 CFU S. suis strain 7997 or put in contact 
with the inoculated pigs. The treated pigs received, both nasally and orally, 5 ml saline 
solutions containing 1,118 mg of PlySs1 and 430 mg of PlySs2 twice daily. Untreated 


























The PlySs1 + PlySs2 drug interaction test was preliminary, because we did not 
execute a checkerboard broth microdilution assay to fully indicate synergism. 
Nonetheless, in this test, the combination of PlySs1 + PlySs2 was greater than either used 
at the same concentration individually (Figure 8.1), which is the definition of synergism. 
From colony counts collected from individual minipigs (data not shown), it seems 
as though the inoculation-colonized minipigs carried higher levels of S. suis strain 7997 
than the contact-inoculated animals. This is the best explanation for all of the minipigs 
contact-colonized surviving. Often, in situ, mother sows colonized with S. suis pass the 
pathogen to her piglets through contact. This transmission did not occur to the same 
extent in our study. 
This study indicated very promising applications for PlySs1 + PlySs2 given their 
ability to protect 80% of minipigs inoculated with S. suis strain 7997 where only 20% of 
the controls survived. The results from this initial minipig study were very promising and 
led to further studies slated for submission to a journal later this year. Given PlySs2’s 
novel structure, and higher activity against S. suis and other pathogens, we proceeded to 
focus on PlySs2 for all future in vivo S. suis studies after this minipig model. 
8.1.5 ACKNOWLEDGEMENTS 
Dr. Jonathan Schmitz purified all of the PlySs1 for the minipig study and aided in 
the shipping of all material. I am very thankful for Dr. Niels Dekker and Dr. Jaap 
Wagenaar of Utrecht University designed and executed the minipig S. suis infection 
model. 





Animals contain symbiotic bacterial microbiomes composed of both commensal 
and pathogenic species. In humans, the cells of the gut microbiome outnumber human 
cells 10:1 (Berg 1996). Commensal bacteria assist in many of our bodily functions 
providing both digestive and immunologic benefits. They enable us to absorb nutrients 
from fibers our cells are unable to metabolize. Further, bacteria provide an intricate 
system of defenses within the body, suppressing pathogenic bacteria, and presenting 
antigens against which we develop antibodies. 
Broad-spectrum, systemic antibiotics kill many commensals in addition to the 
pathogenic bacteria species causing the illness. This often causes diarrhea, which can lead 
to dehydration. Prolonged use can allow pathogenic bacteria (lying outside of the 
antibiotic’s spectrum of efficacy) to flourish such as C. difficile (Kuijper et al. 2006). 
A key benefit to using phage lysins is their specificity. This maximizes their rapid 
action against a single target. Lytic specificity should limit the perturbation to the 
microbiome of the patient. In order to test this hypothesis, we attempted to reduce a 
genus of bacteria and evaluate the effect on other bacterial levels in that environment. 
ClyS was the best lysin for this study. All the other lysins are either too broad, or 
act on bacteria not typically found in the rat oral cavity. 
8.2.2 MATERIALS AND METHODS 
The rats were male Sprague Dawley rats (Strain Code 400 from Charles River), 
weighing 150-250 grams, born on the same date. Samples for culture were taken in 
preliminary experiments. These samples confirmed that a 2-log drop occurred in vivo 




taken before and after treatment (data not shows). Two morphologies were observed on 
staph-selective mannitol plates - a small white one, and the other yellow and smooth. 
Both the yellow and white staph were sensitive to PlySs2 (data not shown). I did a 
straight-forward lytic assay (reduced OD600 absorbance) taking readings every minute 
over an hour of exposure to varying concentrations of PlySs2 from 16-500 µg/ml. Each 
was suspended in BHI media with 25% glycerol. Aliquots were shipped to collaborators 
for sequencing to establish exactly which strains to expect to observe a reduction. 
In the final test, all rats were given one week to acclimate in our animal facility 
and environment. Then, across two weeks, the oral cavities of 14 rats were sampled daily, 
day 1 through day 8. On day 8, nine rats were treated with lysin while the remaining rats 
received an equal volume of vehicle. All rats were housed individually and numbered. 
Each rat was treated with 200 µl of 1 mg/ml ClyS or its vehicle for 15 minutes (while 
anesthetized) twice, over 2 hours. After the first treatment, rats were placed in new 
bedding without food or water. Thirty minutes after the second treatment, fresh food and 
water were provided. After treatment the rats were additionally swabbed 4 hours after 
each being treated with ClyS or control vehicle. The oral cavities were then sampled 
daily until day 15. Thereafter, rats were sampled weekly, day 22, and day 29. 
Furthermore, at each sample collection, 1-2 fresh fecal pellets were also obtained with 
sterile tweezers for additional microbiological analysis.  
Samples were collected from the oral cavity by inserting a single swab and rolling 
it over the back of the tongue (approx. 3-4 cm from the tip of the tongue). This single 
swab samples the tongue, cheeks, roof of the mouth, and top of the throat. Separate swabs 




frozen at -80°C. Following the standard protocols from the Human Microbiome Project, 
we employed sterile Catch-AllTM sample collection swabs from Epicentre 
Biotechnologies (Madison, WI) for all oral sample collection (Aagaard et al. 2013). 
All samples were collected in freezing vials that did not contain any preservatives. 
They were subsequently stored at -80°C immediately after collection, to minimize any 
growth that may alter the composition of the microbial samples. For transport, samples 
were placed on dry ice in a styrofoam container with the lid secured and shipped 
overnight by FedEx®. The samples never thawed during shipment. No culture samples 
were taken from the animals in the test to minimize disruption from multiple swabs. 
Two rats of the 14 rats died during the study due to suffocation during oral 
treatment. Therefore, in the following results, the test rat numbers are 1, 2, 3, 4, 5, 7, 9, 
10, 11. The controls rat numbers are 12, 13, 14. This nonlinear numbering comes from 
the deceased rats being previously labeled 6 and 8. In total, 232 swabs and 164 pellets 
were shipped; near 400 samples in total. To determine background DNA levels, our 
collaborators extracted DNA from devices used for sample acquisition, storage and 
extraction (e.g. tubes, swabs). 
8.2.3 RESULTS 
The test run yielded a 1-2 log drop (reducing the S. aureus to an average of 
approximately 1-10% its original levels in 5 rats). In a couple rats, there was about a 100-
fold reduction, while a few had reduction was less than even 10-fold. In the three controls 





 The S. aureus 16S rDNA level was near the threshold of detection, so our 
collaborators decided to re-sequence some of the samples to obtain more sequences in 
total per sample. Our collaborators plan to set up a Staph qPCR assay. Interestingly, they 
found a non-staphyloccal strain of interest, in which the operational taxonomic unit 
(OUT) is significantly reduced within the oral microbiota 4 hours after treatment. It 
shows no sensitivity to ClyS. Past work indicates that this strain may have a metabolic 
dependence on other organisms such as S. aureus. 
 It seems as though ClyS has a subtle effect on the oral cavity. The two most 
dominant genera in the rat oral cavity before treatment are Actinobacteria (Rothia) and 
streptococci. Both are resistant to ClyS, and their relative levels do not seem to change 
after treatment. There may be significant changes among low-abundant taxa, but 
resequencing will be needed to provide more resolution. Initially, it seemed as though 
some commensal staph strains increased short-term after lysin treatment although there 
was no increase in S. aureus. Further testing will need to confirm whether these staph 
species occupy the niche vacated by S. aureus lysis. On average, there was an increase of 













Figure 8.3 There were two predominant phyla in the oral cavity. 
Most of the bacteria, by genomic quantification, belong to the bacterial phyla 
Actinobacteria and Firmicutes. These two phyla compose approximately 70% and 20%, 
respectively, of the species by number. Combined, they accounted for at least 60% of the 







Our collaborators are currently re-sequencing samples for higher resolution to 
gather more subtle changes that may have occurred after treatment. The two main issues 
that must be addressed are: [1] if the staph in the test rats of the first test were 
significantly reduced, and [2] had some consistent affect on other species as compared to 
the controls. 
8.2.4 DISCUSSION 
Lysins should have less effect on any microbiome due to their specificity. ClyS 
seems to have had a minimal effect on the rat oral cavity. More sequencing will be 
necessary to confirm the degree to which ClyS removed S. aureus. Nonetheless, if S. 
aureus was dramatically decreased, the minimal effect would support the theory that 
lysins are less disruptive to a system than broad-spectrum antibiotics. 
This is a very preliminary experiment, so there are a number of variables one 
would want to mitigate upon repeating a similar study. From the start, we planned to 
retroactively test ClyS against other species of interest after sequencing the rat oral 
microbiota. It may also be worth also examining isoflurane effects by swabbing a few 
new Sprague-Dawley rats before and after 15 minutes exposure to isoflurane. We could 
also test any affect of the swabs as well. However, any perturbations to the microbiome 
within the mouth due to daily swabbing, twice on day 7, and anesthetization should be 
seen or accounted for in the control as well. In the future, it would be good to get swabs 






 Complete reduction of S. aureus was not necessary, just a couple logs so that it 
would show up in the sequencing of the microbiota in the test rats. One would expect 
there to always be some S. aureus persisting in crevices of the oral cavity. It would also 
be good to get all numbers (colony counts, sequencing reads, etc.) from the same 
experiment (rats). A strength of this study is that either result from S. aureus removal 
(other species affected OR not affected) would be important. A main concern i the 
possible challenge of knocking down S. aureus with certainty in the tests versus controls. 
It also seems that the coprophagous behavior of the rats contaminated a few of the oral 
swabs and thus other methods to reduce this variable may be necessary. 
Since the most dramatic shifts in number seem to be among taxa of relatively low 
abundance, our collaborators have to execute very deep sequencing to resolve the 
changes in number among these species. This work also has the importance of surveying 
the microbiota of the rat oral cavity, which has not been well characterized to date (even 
if specific to this distributor and these rats). 
In the future it may be worth trying the following experimental design. Infect 
mice with S. aureus as in the aforementioned bacteremia model. Then, treat with a very 
broad spectrum antibiotic or ClyS injected IP, daily for 14 days. Sample retrieval would 
be a challenge throughout the study, but collecting fecal pellets daily might reveal some 
gut microbiota changes. At the end of the 14 days, the mice could be killed and their 
entire intestinal tract could be removed (end to end, clamped, washed, and frozen, or even 
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8.3 Structural studies 
8.3.1 BACKGROUND 
A few lysin structures have been solved – there are approximately 10 in Protein 
Data Bank (PDB) as of early 2014. Given PlySs2’s unique domain sequence, we sought 
to solve the structure of this novel phage lysin. So far, the results have not led to a 
diffraction pattern from which we can solve the structure. Nonetheless, extensive 
screening of crystallization conditions has yielded crystals in multiple conditions. 
8.3.2 METHODS 
Purified PlySs2 protein was buffer exchanged into 25 mM Tris / 50 mM NaCl 
during a polishing step using size exclusion chromatography (HiLoad 16/60 Superdex 75 
pg, GE Healthcare). Fractions were analyzed using SDS-PAGE and those that contained 
protein corresponding to the MW of PlySs2 were pooled and concentrated to 15 mgs/ml 
for use in vapor-diffusion crystallization trials. Initial hits were obtained in sparse-matrix 
screens using the sitting drop method at a 1:1 mixture of protein and mother liquor in a 
drop volume of 0.6 µl. Subsequent fine screening of conditions and seeding experiments 
were carried out using the hanging drop technique and larger drop and mother liquor 
volumes (1-10 µl and 0.5-1 ml, respectively). Protein concentration was also screened as 





For crystallization, the most promising conditions contained 40-50% (v/v) 2-
methyl-2,4-pentadiol and 0.1 M Tris buffer, in a pH range of 8-8.6 (Figure 8.4). Protein 
crystals, confirmed by UV light imaging, were mounted in fiber loops ranging in size 
from 0.05-0.5 mm, flash frozen in a nitrogen stream at 100 K, and subjected to diffraction 
experiments using either a rotating anode X-ray generator at our home source or 
synchrotron radiation at Brookhaven National Synchrotron Light Source beamline X29. 
Crystallization and diffraction experiments are ongoing. To date, more than 200 crystals 
have been screened, and although diffraction has been detected, none of the data has been 






















Figure 8.4 Crystal of PlySs2. 
This crystal, which is approximately 100 µm, resulted from PlySs2 at 9 mg/ml mixed 
with a crystallization cocktail of 40-50% (v/v) 2-methyl-2,4-pentadiol and 0.1 M Tris 









8.4 DNA AND AMINO ACID SEQUENCES 
 
PlySs2 
- GenBank Accession Number: ZP_03625529 (from S. suis strain 89/1591) 
- 738 base pairs; 245 amino acids; 26.06 kDa; Theoretical pI = 9.06 
 
PlySs2 nucleotide sequence: 
ATGACAACAG TAAATGAAGC ATTAAATAAT GTAAGAGCTC AGGTTGGGTC 
CGGTGTGTCT GTTGGCAACG GCGAATGCTA CGCTTTGGCT AGTTGGTACG 
AGCGCATGAT TAGTCCGGAT GCAACTGTCG GACTTGGCGC TGGTGTGGGC 
TGGGTCAGCG GTGCAATCGG CGATACAATC TCTGCCAAAA ACATCGGCTC 
ATCATACAAC TGGCAAGCTA ACGGCTGGAC AGTTTCCACA TCTGGTCCAT 
TTAAAGCAGG TCAGATTGTG ACGCTTGGGG CAACACCAGG AAACCCTTAC 
GGACATGTGG TAATCGTCGA AGCAGTGGAC GGCGATAGAT TGACTATTTT 
GGAGCAAAAC TACGGCGGGA AACGTTATCC CGTCCGTAAT TATTACAGCG 
CTGCAAGCTA TCGTCAACAG GTCGTGCATT ACATCACACC GCCTGGCACG 
GTCGCACAGT CAGCACCCAA CCTTGCAGGC TCTCGTTCCT ATCGCGAGAC 
GGGCACTATG ACTGTCACGG TCGATGCTCT CAATGTTCGC AGGGCGCCAA 
ATACTTCAGG CGAGATTGTA GCAGTATACA AGCGTGGTGA ATCATTTGAC 
TATGATACTG TCATCATCGA TGTCAATGGC TATGTCTGGG TGTCTTACAT 
AGGCGGCAGC GGCAAACGTA ACTACGTTGC GACGGGCGCT ACCAAAGACG 




PlySs2 amino acid sequence: 
MTTVNEALNN VRAQVGSGVS VGNGECYALA SWYERMISPD ATVGLGAGVG 
WVSGAIGDTI SAKNIGSSYN WQANGWTVST SGPFKAGQIV TLGATPGNPY 
GHVVIVEAVD GDRLTILEQN YGGKRYPVRN YYSAASYRQQ VVHYITPPGT 
VAQSAPNLAG SRSYRETGTM TVTVDALNVR RAPNTSGEIV AVYKRGESFD 
YDTVIIDVNG YVWVSYIGGS GKRNYVATGA TKDGKRFGNA WGTFK 
- CHAP enzymatic domain (PF05257) 
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